

STATE OF WEST VIRGINIA



RETIREE HEALTH BENEFIT TRUST FUND

Fiscal Year 2015 Financial Report

Fiscal Years 2015-2020

September 2015



415 Main Street Reisterstown, MD 21136

Email: info@ccrcactuaries.com

Phone: 410-833-4220 Fax: 410-833-4229

Finance Board West Virginia Retiree Health Benefit Trust Fund 601 57th St., SE, Suite 2 Charleston, West Virginia 25304-2345

Ladies and Gentlemen:

I, Dave Bond, am a Fellow of the Society of Actuaries, a Member of the American Academy of Actuaries, and the Managing Partner in the firm of CCRC Actuaries, LLC ("CCRC Actuaries").

During the 2006 Regular Session of the West Virginia Legislature, House Bill 4654 was enacted creating the West Virginia Retiree Health Benefit Trust Fund ("Trust Fund" or "RHBT") for the purpose of providing for and administering retiree post-employment health care benefits, and the respective revenues and costs of those benefits as a cost sharing multiple employer plan. The Public Employees Insurance Agency ("PEIA"), on behalf of the Public Employees Insurance Agency Finance Board ("Board"), is responsible for the day-to-day operation of the Trust Fund, including all administrative functions.

Statutory provisions governing the Trust Fund require the actuary retained by the PEIA to provide technical advice regarding the operation of the Trust Fund. Using the actuarial assumptions most recently adopted by the Board, the actuary is required to develop actuarial valuations of normal cost, actuarial liability, actuarial value of assets, and related actuarial present values for the West Virginia plan for other post-employment benefits including health insurance. Consequently, the Board has requested CCRC Actuaries to prepare a report separating the actuarial projections for the Trust Fund from the PEIA forecast report. The West Virginia Retiree Health Benefit Trust Fund has assumed the financial liabilities of the retiree programs previously under the PEIA effective July 1, 2006.

The provisions of the Code of West Virginia ("Code"), 1931, as amended, charge the Board with the responsibility to prepare a proposed financial plan designed to generate revenues sufficient to meet all estimated program and administrative costs of the RHBT, including incurred but unreported claims, for the fiscal year for which the plan is proposed. CCRC Actuaries has been retained by the RHBT to review the proposed financial plan for FY 2016, and as supported by our work, to render an actuarial opinion stating whether the plan may be reasonably expected to generate sufficient revenues to meet estimated insurance program and administrative costs of the plan through FY 2020. Our analysis is developed on an accrued and incurred reporting basis for a projection period of five years as required by the Code.

The Code provisions also require the Board to establish and maintain a reserve fund for PEIA for the purposes of offsetting unanticipated claim losses in any fiscal year. Beginning with the Fiscal Year 2002 plan and for each succeeding fiscal year plan, the Board shall transfer ten percent of the projected total plan costs for that year into the reserve fund, which is to be certified by the actuary and included in the final, approved financial plan submitted to the Governor and Legislature in accordance with the provisions of the Code. Any moneys saved in a plan year shall be transferred into the reserve fund. At the close of any fiscal year in which the balance in the reserve fund exceeds the recommended reserve amount by fifteen percent, these excess funds shall be transferred to the West Virginia Retiree Health Benefit Trust Fund.

CCRC Actuaries has provided financial report for fiscal year ending June 30, 2015 ("FY 2015") and preliminary forecasts for fiscal years ending June 30, 2016 ("FY 2016"), June 30, 2017 ("FY 2017"), June 30, 2018 ("FY 2018"), June 30, 2019 ("FY 2019") and June 30, 2020 ("FY 2020"). Our opinion of plan adequacy is based on the projections through FY 2020 using updated future revenue and plan modifications provided by the Board in the plan adopted in December 2014.

Effective July 1, 2012, RHBT has contracted with Humana to provide a Medicare Advantage Plan ("Humana MAPD") benefit to Medicare-eligible retired employees and their Medicare-eligible dependents. Under this arrangement, Humana has assumed the financial risk of providing comprehensive medical and drug coverage with limited copayments. Non-Medicare retirees will continue enrollment in PEIA's Preferred Provider Benefit or the Managed Care Option.

Current Medicare coverages are transferred from a self-insured secondary basis by RHBT to the Humana MAPD plan. However, it should be noted that new Medicare eligible retirees, who become Medicare eligible during the calendar year, will be covered on a secondary basis by the PPB Plan until the beginning of the next calendar year.

The Medicaid / RHBT Hospital Bill ("Bill") has been extended and is anticipated to continue to provide RHBT with hospital charge savings through discounts for all retiree non-Medicare coverages. These hospital savings are assumed to increase by the medical trend assumptions in Fiscal Year 2016 and subsequently. We are assuming that the Bill will continue throughout the five year forecast period.

In reviewing the plan, CCRC Actuaries utilized information concerning the plan's prior experience, covered individuals, plan revenues, plan benefits, plan administrative costs, and other expenses. This information was developed and provided by RHBT, the plan's third party administrators and other sources. In our review, we completely relied on the accuracy of this information and did not perform any due diligence on the information. The enclosed forecasts include anticipated changes from the federal statute Patient Protection and Affordable Care Act ("PPACA") signed into law on March 23, 2010. Additional details of the benefit enhancements and costs can be found later in this report. In addition, it is noteworthy that some current RHBT members may become eligible for the West Virginia Children Health Insurance Plan effective in Fiscal Year 2015. This report does not include anticipated savings from this eligibility change since the proposal has not been finalized and approved by CMS.

In FY 2015 the Pay Go is equivalent to \$307 per retiree per month. In future years, the Pay Go premium may increase by a maximum of 3% per retiree per year, indexed to the initial fixed subsidy determined in FY 2013. The new Pay Go premium formula is based on the financial plan approved by the Financial Board in December 2014.

Senate Bill 469, effective July 1, 2012, amended West Virginia code (the Code) section 11-21-96 by dedicating \$30 million to be transferred annually from personal income tax previously collected for payment of the unfunded liability of the Workers' Compensation fund to the Retiree Health Benefit Trust fund (RHBT). Transfers will not commence until the Workers' Compensation fund has be certified by the Governor to the Legislature to be paid or provided for in its entirety. Thereafter, transfers will be made until the RHBT fund has been provided for in its entirety or July 1, 2037, whichever date is later. Presently RHBT estimates that the aforementioned \$30 million transfers will likely commence in 2017. All Employers will receive benefit of these contributions.

Based on our review, and subject to the conditions described herein, we believe the financial plan approved by the Board for FY 2015 through FY 2020 may be reasonably expected to generate sufficient revenues, when combined with the existing surplus, to meet estimated insurance program and administrative costs of the Trust Fund.

This conclusion is based on significant revenue increases in employer, employee, and retiree premiums in later fiscal years of the plan through FY 2020 as approved by the Board in December 2014.

The preparation of any estimate of future health costs requires consideration of a broad array of complex social and economic events. Changes in reimbursement methodology, the emergence of new and expensive medical procedures and prescription drugs options, and the continuing evolution and changes of the framework of MAPD plan and other managed care options impacting Non-Medicare retirees, as are contemplated in the Board's proposed plan, increase the level of uncertainty of such estimates. As such, the estimate costs of insurance program contain considerable uncertainty and variability and actual experience may not conform to the assumptions utilized in this report.

Respectfully,

Dave Bond

Dave Bond, F.S.A., F.C.A., M.A.A.A. Managing Partner

Christian . Berit

Chris Borcik, F.S.A., F.C.A., M.A.A.A. Senior Actuarial Consultant

West Virginia Retiree Health Benefit Trust Fund Report of Independent Actuary Financial Plan for FY 2015 – FY 2020

OVERVIEW

This report analyzes revenues and expenses related to funding the health insurance benefits of retired employees of the State of West Virginia and various local agencies, together with their dependents. This report is intended for the sole use of the Board, and any other use requires written approval by CCRC Actuaries.

This report was compiled utilizing claims data collected by RHBT's third party administrators through August 2015 for prescription drugs and medical claims. Enrollment data, administrative expenses, managed care capitations, and plan revenues were provided at special request from RHBT. Revenue assumptions are based on premium rates, assumed investment income and significant general and special revenue allocations provided by the Governor, some which have not been approved by the West Virginia Legislature. In addition, other information became available through presentations made at Board meetings, which has been used in arriving at our conclusions.

The Code of West Virginia establishes the actuarial reporting requirements for the Trust Fund on an incurred basis for medical claims, prescription drug claims and capitations, and on an accrued basis for administrative expenses and revenue for a period of five years. The Fund represents state and local agency retirees and their survivors. The Trust Fund is allocated its share of administrative costs from PEIA.

KEY ASSUMPTIONS

A. Enrollment Changes

The Board has requested that the projection assume retiree enrollment growth consistent with the experience of the plan. These projections assume that the Trust Fund will annually have 1,000 additional retirees. We have observed a net increase of 1,030 retirees from June 2014 to June 2015, approximating our current assumption. CCRC Actuaries has updated the claims analysis based on the enrollment through September 2015.

In aggregate, September 2015 enrollment has increased by 852 coverages since the end of FY 2015. Aggregate Preferred Provider Benefit ("PPB") enrollment has increased by 827 in total over the same period, while managed care enrollment continues to cover fewer participants with a slight increase of 25 coverages. For MAPD Capitations, 40,920 Medicare policyholders were projected to forecast the monthly capitation cost shown on Page 8 of this report.

The following chart summarizes the current enrollment as of the selected monthly billing dates of June 2014, June 2015 and September 2015 for purposes of comparison:

Trust Fund		Preferre	d Provider	Benefit*	Managed Care		
	Coverage	Jun-14	Jun-15	Sep-15	Jun-14	Jun-15	Sep-15
Retirees	Medicare Single	18,429	19,018	19,235	-	-	-
	Medicare Family	13,316	13,860	14,090		_	_
	Medicare Total	31,745	32,878	33,325	-	-	-
	Non Medicare Single	3,517	3,462	3,584	159	149	163
	Non Medicare Family	4,384	4,356	4,614	176	166	177
	Non Medicare Total	7,901	7,818	8,198	335	315	340
	Retiree Total	39,646	40,696	41,523	335	315	340
	Grand Total				39,981	41,011	41,863

* The majority of PPB is capitated through Humana. As of August 2015, there are approximately 1,899 Medicare retiree coverages under PEIA.

B. Changes in Claim Backlog

Detail of the medical claim backlog is presented in the PEIA report titled "PEIA Fiscal Year 2015 Financial Report".

C. Trend Analysis

CCRC Actuaries performed the detailed medical and prescription drugs trend analysis in the report titled, "Detailed Medical and Prescription Drugs Claim Trend Report - September 2014". This report includes the detailed trend analysis of PEIA experience by medical and prescription drugs. Based on the analysis, the FY 2016 medical claim trend is 5.5% and the prescription drugs trend is 8.5%.

The current trends projection is shown in the following table:

Claim Type	FY 2016 Trend					
Non-Medicare – Medical	5.5%					
Medicare – Medical	5.5%					
Non-Medicare – Drugs	8.5%					
Medicare – Drugs	8.5%					

In addition, we have assumed that trends will increase by 0.5% in each successive fiscal year beginning in FY 2017. At the Board's request, the baseline trend assumptions have been established to reflect the most likely or expected trends.

The following chart summarizes the trend results observed for the plan using data through August 2015. It is important to note that these trends <u>have not</u> been adjusted to reflect savings as a result of the expansion of the drug rebate program or the claim savings due to changes in provider reimbursement methodologies nor changes in the benefit structure. In developing the claim cost projection, we have reflected for benefit and reimbursement changes as an adjustment to the gross trend assumption.

Aggregate Trust Fund Historical Trends (Retirees)

Fiscal <u>Year</u>	Medical <u>Medicare</u>	Medical <u>Non-Medicare</u>	Drugs <u>Medicare</u>	Drugs <u>Non-Medicare</u>	<u>Total</u>
2004	9%	2%	3%	-2%	6%
2005	6%	-2%	16%	1%	8%
2006	6%	5%	11%	17%	9%
2007	6%	1%	6%	6%	5%
2008	N/A	6%	N/A	-9%	N/A
2009	N/A	-1%	N/A	5%	N/A
2010	N/A	3%	N/A	7%	N/A
2011	N/A	11%	N/A	16%	N/A
2012	-5%	-6%	2%	8%	-2%
2013	23%	-3%	-3%	-7%	-2%
2014	N/A	7%	N/A	6%	N/A
2015	N/A	7%	N/A	6%	N/A
2016*	N/A	9%	N/A	4%	N/A

* Fiscal Year 2016 results are through the first two months ending August 2015. It should be noted that Humana's plan year starts in January in calendar year basis (not starting in July as in PEIA plan year basis) and the Medicare trends are not statistically credible.

Effective July 1, 2007, PEIA had contracted with Coventry Advantra Freedom to provide Medicare Advantage/Prescription Drug Plan ("Coventry MA and PDP") Benefits to Medicare-eligible retired employees and dependents. Under this arrangement, Coventry Advantra Freedom had assumed the financial risk of providing comprehensive medical and prescription drug coverage with limited copayments. This arrangement expired on June 30, 2010. As a result, Fiscal Year 2008 through 2011 Medicare trends are not statistically credible.

It should be noted that RHBT left the Coventry MA and PDP program as of June 30, 2012, and RHBT assigned Medicare eligible retirees to the Humana MAPD program starting July 1, 2012.

D. Enrollment, Claim, Expense and Revenue Assumptions

Using aggregate PEIA and Trust Fund paid claim data through August 2015 for medical claims and for prescription drugs claims, average annualized incurred unit claim costs were developed for the Trust Fund for both self-funded and managed care coverages. CCRC Actuaries has developed the claim cost on an adjusted exposure basis using the respective expected claim cost for each coverage type. The adjusted exposure methodology weighs the expected claim cost under each coverage type for single, member and children, and family coverages based on observed differences in health care cost. For example, under this methodology single coverage types are given a weight of 1.0 exposure, whereas member and children coverages are given a greater weighting based on historical expected health care cost relationships. Based on this methodology, the result of FY 2015 and the projection of FY 2016 revenue and expenses are summarized in the following chart. It should be noted that the chart reflects per policy information.

iscal Yea	ar 2015 Result			Reve	enue				Expenses		5	
			1	Monthly		Monthly	N	Aonthly	N	Ionthly		Monthly
			E	mployer	E	mployee]	Medical		Drugs	С	apitation
Fund	Program	Policies	Pr	emiums	P	remiums		Costs		Costs*		Costs
Retiree	Medicare Humana and Express Scripts <u>Non-Medicare</u> Total Non-Medicare	32,465 <u>8,129</u> 40,594	\$	-	\$	162	\$ \$	128** 704		180** 250	\$	340
	<u>Managed Care</u> Total	<u>326</u> 40,920	\$	-	\$	551					\$	1,142

*Net of rebates and subsidies.

** As of June 2015, there are approximately 1,373 Medicare coverages that were not capitated through Humana.

Fiscal Yea	ar 2016 Projection			Reve	enue				E	xpenses	5	
			1	Monthly		Monthly	I	Monthly Monthly			Monthly	
			E	mployer	E	mployee]	Medical		Drugs	C	apitation
Fund	Program	Policies	Pr	emiums	P	remiums		Costs		Costs*		Costs
Retiree	Medicare Humana and Express Scripts <u>Non-Medicare</u> Total Non-Medicare	33,449 <u>8,343</u> 41,792	\$	-	\$	165	\$ \$	127** 710	·	183** 250		359
	<u>Managed Care</u> Total	<u>340</u> 42,132	\$	-	\$	564					\$	1,039

*Net of rebates and subsidies.

** As of August 2015, there are approximately 1,899 Medicare coverages that were not capitated through Humana.

Projected plan revenues and administrative expenses were provided by RHBT. The following chart summarizes the Financial Plan adopted by the Board in December 2014. Both Medicare and Non-Medicare retirees premium received no increases in Fiscal Year 2015 and 2016.

Board Decisions – December 2014

	Fiscal Year					
Source	2015	2016	2017	2018	2019	2020
Additional Retiree Premium	\$0	\$0	\$4,380,722	\$18,937,242	\$21,377,582	\$26,987,410
General Revenue Transfer	\$0	\$0	\$30,000,000	\$30,000,000	\$30,000,000	\$30,000,000
Benefit Reductions/(Increase) -						
Retiree Non-Medicare	\$0	\$3,900,000	\$0	\$0	\$0	\$0
Benefit Reductions/(Increase) -						
Managed Care Capitations	\$0	\$584,103	\$0	\$0	\$0	\$0
Benefit Reductions/(Increase) -						
Humana MAPD (calendar year)	\$0	\$1,808,772	\$2,291,228	\$0	\$0	\$0
ACA Reinsurance						
Contributions (Cost)	(\$849,996)	(\$550,000)	(\$200,000)	\$0	\$0	\$0
ACA Comparative						
Effectiveness Research Fees						
(Cost)	(\$30,083)	(\$30,826)	(\$31,601)	(\$32,408)	(\$33,249)	\$0
Pay Go Premium Transfer	\$150,549,744	\$150,000,000	\$180,000,000	\$195,000,000	\$210,000,000	\$220,000,000
Actuarial Accrued Liability*	\$3,585,500,000	\$3,743,700,000	\$3,899,600,000	\$4,044,600,000	\$4,181,000,000	\$4,297,300,000
Funded Status	19.7%	19.5%	20.4%	21.5%	22.7%	24.2%

*Projected Result

The \$3,900,000 of Retiree Non-Medicare benefit reductions in Fiscal Year 2016 is comprised of the following:

2016 Claim Cost Savings \$2.2 M \$1.7 M

Medical Claims Drug Claims A detailed list of the benefit reductions for the Non-Medicare Retirees as voted on by the Board consists of the following:

	<u>Savings</u>
Increase Primary Care Office Visit copayment from \$15 to \$20 per visit	\$0.15 M
Increase Specialist Office Visit copayment from \$25 to \$40 per visit	\$0.52 M
Increase deductible by \$25 for single coverage and \$50 for family coverage	\$0.26 M
Increase outpatient surgery copay from \$50 to \$100	\$0.25 M
Increase emergency room copay to \$100 with no discount	\$0.07 M
Increase family out-of-pocket maximum for PEIA PPB Plans A and D to	
twice the employee only amount	\$0.84 M
Add \$100 copay per admission to existing deductible and 20% coinsurance	
for inpatient hospital care	\$0.15 M
Increase Generic Drug Copay for 30 day supply from \$5 to \$10 and for 90	
day supply (maintenance only) from \$10 to \$20	\$1.27 M
Increase Preferred Brand Drug Copay for 30 day supply from \$15 to \$25 and	
for 90 day supply (maintenance only) from \$30 to \$50	\$0.42 M

The \$4,100,000 of Humana MAPD benefit reductions occurs in calendar year 2016, and can be translated to the following savings in FY 2016 and FY2017:

Fiscal Year 2016	\$1.8 M
Fiscal Year 2017	\$2.3 M

A detailed listing of the Medicare CY 2016 benefit reductions are comprised of the following:

	<u>Savings</u>
Increase copayment for office visits PCP/Specialist from \$10/\$20 to \$20/\$40	\$2.0 M
Increase Outpatient Surgery copayment by \$50 from \$50 to \$100	\$0.3 M
Increase deductible by \$75 per person from \$25 to \$100	\$1.8 M

The Centers for Medicare & Medicaid Services ("CMS") and the United States Department of Health and Human Services ("HHS") released the final rule containing further detail and parameters related to the risk adjustment, reinsurance, and risk corridors programs in the ACA on November 26, 2012. Section 1341 of the ACA provides that health insurance issuers and third party administrators on behalf of group health plans must make payments to an applicable reinsurance entity.

Under the final rule, issuers would be required to pay a reinsurance contribution of \$5.25 per member per month to HHS in 2014. The \$5.25 contribution rate would gradually decrease in 2015 and 2016. From 2017 and beyond, no further reinsurance contributions will be collected. RHBT will not receive any benefit payments from the national reinsurance program. RHBT will be subject to paying the reinsurance contributions through FY 2017 and the projected expenses of the reinsurance contributions are included in the current financial plan. The total reinsurance contributions for the financial projection are estimated to be approximately \$1,600,000, with \$849,996 in FY 2015.

The Treasury Department and the Internal Revenue Service recently issued a final rule implementing a new tax added by the Affordable Care Act: The Comparative Effectiveness Research Fees. These fees are currently expected to be paid by health insurers and plan sponsors of self-insured group health plans.

The Affordable Care Act created a new Patient-Centered Outcomes Research Institute (PCORI) to conduct research evaluating and comparing health outcomes, and assess the clinical effectiveness, risks and benefits of medical treatments. The PCORI's work will be paid for by a new Patient-Centered Outcomes Research Trust Fund, which will be funded in part through the comparative effectiveness research fees.

It is anticipated that RHBT would accrue and pay these fees in FY 2015 through FY 2019. The fee would be \$2 per member per year. The total comparative effectiveness research fees for the financial projection are estimated to be approximately \$158,000, with \$30,083 in FY 2015.

Future fiscal year State revenue increases will require legislative appropriation. Additional retiree premiums represent premiums paid by retirees either directly or through sick and annual leave conversion credits. Additionally, RHBT management has assumed that the Retiree Premium Assistance Program will grow as a direct result from the required retiree premium increases in the financial plan. The program's cost is currently projected to grow from approximately \$2.1 million in FY 2015 to approximately \$2.4 million in FY 2020, based on the Board's direction and projected retiree enrollment growth in the financial plan.

In FY 2015 the Pay Go is equivalent to \$307 per retiree per month. In future years, the Pay Go premium may increase by a maximum of 3% per retiree per year, indexed to the initial fixed subsidy determined in FY 2013. The new Pay Go premium formula is based on the financial plan approved by the Financial Board in December 2014.

E. <u>Provider Reimbursement Changes</u>

Effective July 1, 2012, RHBT has contracted with Humana to provide a Medicare Advantage Plan ("Humana MAPD") benefit to Medicare-eligible retired employees and their Medicare-eligible dependents. Under this arrangement, Humana has assumed the financial risk of providing comprehensive medical and drug coverage with limited copayments. Non-Medicare retirees will continue enrollment in PEIA's Preferred Provider Benefit or the Managed Care Option.

It should be noted that RHBT left the Coventry MA and PDP program as of June 30, 2012, and RHBT assigned Medicare eligible retirees to the Humana MAPD program starting July 1, 2012.

FISCAL YEAR 2015 RESULT

The financial result for FY 2015 under the Baseline scenario is presented in the Appendix. The Baseline forecast for FY 2015 projects accrued revenue of \$291,048,131 and incurred plan expenses of \$267,834,538 to produce a fiscal year surplus of \$13,443,746 after the Premium Stabilization Reserve drawdown of \$9,769,847. The PEIA local and state agencies Pay Go premiums for FY 2015 are \$150,549,744.

FISCAL YEAR 2016 FORECAST

The financial forecast for FY 2016 under the Baseline scenario is presented in the Appendix. The Baseline forecast for FY 2016 projects accrued revenue of \$341,875,564 and incurred plan expenses of \$284,110,975 to produce a fiscal year surplus of \$25,564,589 after the Premium Stabilization Reserve drawdown of \$32,200,000. The PEIA local and state agencies Pay Go premiums for FY 2016 are assumed to be \$150,000,000.

FISCAL YEAR 2017 FORECAST

The financial forecast for FY 2017 under the Baseline scenario is presented in the Appendix. The Baseline forecast for FY 2017 projects accrued revenue of \$383,600,584 and incurred plan expenses of \$309,037,125 to produce a fiscal year surplus of \$63,563,459 after the Premium Stabilization Reserve drawdown of \$11,000,000. The PEIA local and state agencies Pay Go premiums for FY 2017 are assumed to be \$180,000,000.

FISCAL YEAR 2018 FORECAST

The financial forecast for FY 2018 under the Baseline scenario is presented in the Appendix. The Baseline forecast for FY 2018 projects accrued revenue of \$416,606,872 and incurred plan expenses of \$338,146,663 to produce a fiscal year surplus of \$74,020,873 after the Premium Stabilization Reserve drawdown of \$4,439,335. The PEIA local and state agencies Pay Go premiums for FY 2018 are assumed to be \$195,000,000.

FISCAL YEAR 2019 FORECAST

The financial forecast for FY 2019 under the Baseline scenario is presented in the Appendix. The Baseline forecast for FY 2019 projects accrued revenue of \$454,939,322 and incurred plan expenses of \$371,945,794 to produce a fiscal year surplus of \$82,993,529 after the Premium Stabilization Reserve drawdown of \$0. The PEIA local and state agencies Pay Go premiums for FY 2019 are assumed to be \$210,000,000.

FISCAL YEAR 2020 FORECAST

The financial forecast for FY 2020 under the Baseline scenario is presented in the Appendix. The Baseline forecast for FY 2020 projects accrued revenue of \$499,067,823 and incurred plan expenses of \$410,992,484 to produce a fiscal year surplus of \$88,075,339 after the Premium Stabilization Reserve drawdown of \$0. The PEIA local and state agencies Pay Go premiums for FY 2020 are assumed to be \$220,000,000.

LITIGATION

The forecasts presented in the attached tables do not contemplate any additional revenues or expenses to be generated from litigation activities.

SUMMARY

It should be noted that the aggregate PEIA and Trust Fund reserves will meet or exceed the 10% of program expense requirement under the Baseline Scenario assumptions. With projected changes to the plan as adopted in the Board, we are forecasting that the plan will meet the minimum 10% reserve target set by West Virginia Statute through the projection period ending with the Fiscal Year 2020. These projections are based on significant revenue increases as contained in the Financial Plan adopted by the Board in December 2014 and are contingent on legislative approval. These forecasts are based on assumptions including the estimated cost and savings of plan changes, expected trend levels and exposure levels. The continued enrollment changes of the managed care options, changes in physician, ambulatory and hospital provider reimbursement; possible changes in methodology of managed care premium calculation; and changes in the prescription drugs program, can be expected to further exacerbate the difficulty of projecting future medical and drugs claim levels and lags. These projections do not incorporate any anticipated effects of national or state health care reform, such as Medicare and Medicaid reform. As such, actual results deviating from those amounts projected in these pages should not be unexpected. With the legislatively mandated requirement of a five-year projection, it should be assumed that constant modifications would be required.

APPENDIX - BASELINE SCENARIO RHBT - MEDICARE AND NON-MEDICARE

WEST VIRGINIA RETIREE HEALTH BENEFIT TRUST FINANCIAL RESULT FISCAL YEAR 2015

PERIOD 7/1/2014 - 6/30/2015

	to	7/1/2014 0 12/31/2014		1/1/2015 to 6/30/2015		TRUST Total
Revenues WV PEIA Pay Go Premiums Retiree Premiums - PPB Retiree Premiums - MCO Annual Required Contributions Non Par Premiums Life Insurance Investment Income Transfer from Premium Stabilization Reserve Total Revenue	\$	75,274,872 39,410,143 1,084,659 58,516 1,612,257 11,515,162 11,570,828 4,824,285	\$	75,274,872 39,648,231 1,071,982 58,516 1,612,257 11,515,162 11,570,828 4,945,562 145,697,410	\$	150,549,744 79,058,374 2,156,641 117,031 3,224,514 23,030,324 23,141,656 9,769,847 291,048,131
	φ	143,330,721	φ	143,097,410	φ	291,048,131
Program Expenses Non-Medicare Medical Claims Non-Medicare Prescription Drug Claims Medicare Medical Claims Medicare Prescription Drug Claims Non-Medicare Managed Care Capitations Humana MAPD Program Administration Life Insurance Retiree Assistance Program ACA Reinsurance Contributions ACA Comparative Effectiveness Research Fees Director's Discretionary Fund	\$	33,376,609 11,260,027 2,079,570 3,026,465 2,233,304 64,551,572 2,283,045 11,380,244 1,047,366 500,000 15,042 -	\$	35,271,292 13,117,602 1,051,577 1,552,678 2,233,304 67,779,151 2,283,045 11,380,244 1,047,366 350,000 15,042	\$	68,647,901 24,377,629 3,131,147 4,579,143 4,466,607 132,330,723 4,566,090 22,760,487 2,094,732 849,996 30,083 - -
Fiscal Year Results	\$	13,597,479		9,616,111	\$	23,213,593
	Ŷ	10,027,172	Ψ	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Ψ	20,210,070
Beginning Restricted Reserve					\$	633,739,334
Ending Restricted Reserve					\$	656,952,927
Beginning Premium Stabilization Reserve					\$	57,409,182
PSR Addition/(Drawdown)					\$	(9,769,847)
Ending Premium Stabilization Reserve					\$	47,639,335
Total Beginning Plan Reserve					\$	691,148,516
Total Ending Plan Reserve					\$	704,592,263
Accrued Actuarial Liability (AAL)					\$	3,585,500,000
Funded Status						19.7%

Pay Go Monthly Premium for Actives	\$ 163.69	Claim and C	Other Expense Trends	
Additional Retiree Premiums	\$ -	Eligibility	Medical	Drugs
Pay Go PEPM Subsidy for Retirees	\$ 306.59	Non-Medicare	5.0%	8.0%
		Medicare	5.0%	8.0%
		Capitations		-7.6%
		Administrative Expense		3.5%
Number of Net New Retirees	1,000	Pay Go Monthly Premium		-6.8%

APPENDIX - BASELINE SCENARIO <u>RHBT - MEDICARE</u>

WEST VIRGINIA RETIREE HEALTH BENEFIT TRUST FINANCIAL RESULT FISCAL YEAR 2015

PERIOD 7/1/2014 - 6/30/2015

Medicare Retiree	Baseline Projection	Board Decision	Ending Projection
Revenues WV PEIA Pay Go Premiums Employer Premiums - PPB Employer Premiums - MCO Retiree Premiums - PPB Retiree Premiums - MCO Annual Required Contributions Non Par Premiums Life Insurance Investment Income Transfer from Premium Stabilization Reserve	\$ 90,495,848 7,628,009 - 34,984,372 - 1,691,857 12,083,689 12,287,144 6,579,693 165,750,612	\$ - -	\$ 90,495,848 7,628,009 - 34,984,372 - 1,691,857 12,083,689 12,287,144 6,579,693 165,750,612
<u>Program Expenses</u> Medicare Medical Claims Medicare Prescription Drug Claims Humana MAPD Program Administration Life Insurance Retiree Assistance Program ACA Reinsurance Contributions ACA Comparative Effectiveness Research Fees Director's Discretionary Fund	\$ 3,131,147 4,579,143 132,330,723 1,685,468 11,942,109 1,099,077 - 22,203	\$ -	\$ 3,131,147 4,579,143 132,330,723 1,685,468 11,942,109 1,099,077 - 22,203 -
Total Expenses	\$ 154,789,870	\$ -	\$ 154,789,870
Fiscal Year Results	\$ 10,960,742		\$ 10,960,742
Beginning Restricted Reserve	\$ 324,411,552		\$ 324,411,552
Ending Restricted Reserve	\$ 335,372,294		\$ 335,372,294
Beginning Premium Stabilization Reserve	\$ 42,564,009		\$ 42,564,009
PSR Addition/(Drawdown)	\$ (6,579,693)		\$ (6,579,693)
Ending Premium Stabilization Reserve	\$ 35,984,316		\$ 35,984,316
Total Beginning Plan Reserve	366,967,751		366,967,751
Total Ending Plan Reserve	\$ 371,356,611		\$ 371,356,611
Accrued Actuarial Liability (AAL)	\$ 3,585,500,000		\$ 3,585,500,000
Funded Status	19.7%		19.7%

Pay Go Monthly Premium for Actives	\$ 163.69	Claim	and Other Expense Trends	
Additional Retiree Premiums	\$ -	Eligibility	Medical	Drugs
Pay Go PEPM Subsidy for Retirees	\$ 232.29	Medicare	5.0%	8.0%
	I	Capitations		-7.6%
	I	Administrative Expense	e	3.5%
Number of Net New Retirees	700	Pay Go Monthly Premi	um	-6.8%

APPENDIX - BASELINE SCENARIO RHBT - NON-MEDICARE

WEST VIRGINIA RETIREE HEALTH BENEFIT TRUST FINANCIAL RESULT FISCAL YEAR 2015

PERIOD 7/1/2014 - 6/30/2015

Non-Medicare Retiree	Baseline Projection	Board Decision	Ending Projection
Revenues WV PEIA Pay Go Premiums Employer Premiums - PPB Employer Premiums - MCO Retiree Premiums - PPB Retiree Premiums - MCO Annual Required Contributions Non Par Premiums Life Insurance Investment Income Transfer from Premium Stabilization Reserve	\$ 60,053,896 15,165,873 1,345,846 21,280,119 810,794 117,031 1,532,657 10,946,635 10,854,512 3,190,154	-	\$ 60,053,896 15,165,873 1,345,846 21,280,119 810,794 117,031 1,532,657 10,946,635 10,854,512 3,190,154
Total Revenue	\$ 125,297,517	\$ -	\$ 125,297,517
Program Expenses Non-Medicare Medical Claims Non-Medicare Prescription Drug Claims Non-Medicare Managed Care Capitations Administration Life Insurance Retiree Assistance Program ACA Reinsurance Contributions ACA Comparative Effectiveness Research Fees Director's Discretionary Fund	\$ 68,647,901 24,377,629 4,466,607 2,880,622 10,818,378 995,655 849,996 7,880	\$ -	\$ 68,647,901 24,377,629 4,466,607 2,880,622 10,818,378 995,655 849,996 7,880
Total Expenses	\$ 113,044,668	\$ -	\$ 113,044,668
Fiscal Year Results	\$ 12,252,849		\$ 12,252,849
Beginning Restricted Reserve	\$ 309,327,783		\$ 309,327,783
Ending Restricted Reserve	\$ 321,580,632		\$ 321,580,632
Beginning Premium Stabilization Reserve	\$ 14,845,173		\$ 14,845,173
PSR Addition/(Drawdown)	\$ (3,190,154)		\$ (3,190,154)
Ending Premium Stabilization Reserve	\$ 11,655,019		\$ 11,655,019
Total Beginning Plan Reserve	324,180,766		324,180,766
Total Ending Plan Reserve	\$ 333,235,651		\$ 333,235,651
Accrued Actuarial Liability (AAL)	\$ -		\$ -
Funded Status	N/A		N/A

Pay Go Monthly Premium for Actives	\$ 163.69	Claim ar	nd Other Expense Trends	
Additional Retiree Premiums	\$ -	<u>Eligibility</u>	Medical	Drugs
Pay Go PEPM Subsidy for Retirees	\$ 591.90	Non-Medicare	5.0%	8.0%
		Capitations		-7.6%
		Administrative Expense		3.5%
Number of Net New Retirees	300	Pay Go Monthly Premiur	n	-6.8%

APPENDIX - BASELINE SCENARIO RHBT - MEDICARE AND NON-MEDICARE

WEST VIRGINIA RETIREE HEALTH BENEFIT TRUST FINANCIAL FORECAST FISCAL YEAR 2016

PERIOD 7/1/2015 - 6/30/2016

	to	7/1/2015	1	1/1/2016 to 6/30/2016		TRUST Total
Revenues WV PEIA Pay Go Premiums Retiree Premiums - PPB Retiree Premiums - MCO Annual Required Contributions Non Par Premiums Life Insurance Investment Income Transfer from Premium Stabilization Reserve General Revenue Transfer	\$	75,000,000 41,078,263 1,149,887 - 1,563,890 12,090,920 23,684,179 15,948,625 -	\$	75,000,000 41,618,987 1,150,451 - 1,563,890 12,090,920 23,684,179 16,251,375 -	\$	150,000,000 82,697,250 2,300,338 - 3,127,779 24,181,840 47,368,357 32,200,000 -
Total Revenue	\$	170,515,763	\$	171,359,801	\$	341,875,564
Program Expenses Non-Medicare Medical Claims Non-Medicare Prescription Drug Claims Medicare Medical Claims Medicare Prescription Drug Claims Non-Medicare Managed Care Capitations Humana MAPD Program Administration Life Insurance Retiree Assistance Program ACA Reinsurance Contributions ACA Comparative Effectiveness Research Fees Director's Discretionary Fund Total Expenses	\$ \$	34,575,109 11,580,373 2,275,472 3,405,506 2,119,917 69,557,360 2,351,537 11,949,256 878,481 350,000 15,413 151,807 139,210,230	\$	36,537,827 13,490,797 1,108,511 1,683,328 2,119,917 74,413,874 2,351,537 11,949,256 878,481 200,000 15,413 151,807 144,900,746	\$ \$	71,112,936 25,071,170 3,383,983 5,088,834 4,239,833 143,971,233 4,703,073 23,898,511 1,756,962 550,000 30,826 303,614 284,110,975
Fiscal Year Results	\$	31,305,533	\$	26,459,055	\$	57,764,589
Beginning Restricted Reserve Ending Restricted Reserve					\$ \$	656,952,927 714,717,516
Beginning Premium Stabilization Reserve					\$	47,639,335
PSR Addition/(Drawdown)					\$	(32,200,000)
Ending Premium Stabilization Reserve					\$	15,439,335
Total Beginning Plan Reserve					\$	704,592,263
Total Ending Plan Reserve					\$	730,156,851
Accrued Actuarial Liability (AAL)					\$	3,743,700,000
Funded Status						19.5%

KEY	ASSUMPTIONS

	ILL I			
Pay Go Monthly Premium for Actives	\$ 163.09	Claim and O	ther Expense Trends	
Additional Retiree Premiums	\$ -	Eligibility	Medical	Drugs
Pay Go PEPM Subsidy for Retirees	\$ 296.69	Non-Medicare	5.5%	8.5%
		Medicare	5.5%	8.5%
		Capitations		-5.1%
		Administrative Expense		3.0%
Number of Net New Retirees	1,000	Pay Go Monthly Premium		-0.4%

APPENDIX - BASELINE SCENARIO <u>RHBT - MEDICARE</u>

WEST VIRGINIA RETIREE HEALTH BENEFIT TRUST FINANCIAL FORECAST FISCAL YEAR 2016

PERIOD 7/1/2015 - 6/30/2016

Medicare	Basel	line Board	l Ending
Retiree	Project		-
Revenues WV PEIA Pay Go Premiums Employer Premiums - PPB Employer Premiums - MCO Retiree Premiums - MCO Annual Required Contributions Non Par Premiums Life Insurance Investment Income Transfer from Premium Stabilization Reserve General Revenue Transfer	\$ 92,354, 7,904,8 37,165,1	515 333 404 179 - 158 - - 102 873 577	\$ 92,354,615 7,904,833 404 37,165,179 158 - 1,641,102 12,687,873 24,965,577 22,700,000 -
Total Revenue	\$ 199,419,7	741 \$ -	\$ 199,419,741
Program Expenses Medicare Medical Claims Medicare Prescription Drug Claims Humana MAPD Program Administration Life Insurance Retiree Assistance Program ACA Reinsurance Contributions ACA Comparative Effectiveness Research Fees Director's Discretionary Fund	\$ 3,383,5 5,088,5 145,780,0 1,736,0 12,539,2 921,3 23,0		1,736,032 12,539,214 921,853 - 23,025 -
Total Expenses	\$ 169,472,9	946 \$ (1,808,772)) \$ 167,664,174
Fiscal Year Results	\$ 29,946,7	795	\$ 31,755,567
Beginning Restricted Reserve Ending Restricted Reserve	\$ 335,372,2 \$ 365,319,0		\$ 335,372,294 \$ 367,127,862
Beginning Premium Stabilization Reserve	\$ 35,984,3	316	\$ 35,984,316
PSR Addition/(Drawdown)	\$ (22,700,0	000)	\$ (22,700,000)
Ending Premium Stabilization Reserve	\$ 13,284,3	316	<u>\$ 13,284,316</u>
Total Beginning Plan Reserve	371,356,6	511	371,356,611
Total Ending Plan Reserve	\$ 378,603,4	406	\$ 380,412,178
Accrued Actuarial Liability (AAL)	\$ 3,743,700,0	000	\$ 3,743,700,000
Funded Status	19	.3%	19.5%

KET ASSOMITIONS								
Pay Go Monthly Premium for Actives	\$	163.09	Claim and Other Expense Trends					
Additional Retiree Premiums	\$	-	<u>Eligibility</u>	Medical	Drugs			
Pay Go PEPM Subsidy for Retirees	\$	230.09	Medicare	5.5%	8.5%			
			Capitations		-5.1%			
			Administrative Expens	e	3.0%			
Number of Net New Retirees		700	Pay Go Monthly Premi	um	-0.4%			

APPENDIX - BASELINE SCENARIO RHBT - NON-MEDICARE

WEST VIRGINIA RETIREE HEALTH BENEFIT TRUST FINANCIAL FORECAST FISCAL YEAR 2016

PERIOD 7/1/2015 - 6/30/2016

	Baseline Projection		Board Decision		Ending Projection
\$	57,645,385 15,078,565 1,369,691 22,548,674 930,086 - 1,486,677 11,493,967 22,402,780 9,500,000 -			\$	57,645,385 15,078,565 1,369,691 22,548,674 930,086 - 1,486,677 11,493,967 22,402,780 9,500,000
\$	142,455,825	\$	-	\$	142,455,825
\$	73,312,936 26,771,170 4,823,936 2,967,040 11,359,297 835,109 550,000 7,802 303,614 120,930,904	\$	(1,700,000) (584,103)		71,112,936 25,071,170 4,239,833 2,967,040 11,359,297 835,109 550,000 7,802 303,614 116,446,801
\$	21,524,921			\$	26,009,024
\$ \$ \$ \$	321,580,632 343,105,553 11,655,019 (9,500,000) 2,155,019 333,235,651 345,260,573			\$ \$ \$ \$	321,580,632 347,589,656 11,655,019 (9,500,000) 2,155,019 333,235,651 349,744,676
	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	Projection \$ 57,645,385 15,078,565 1,369,691 22,548,674 930,086 - 1,486,677 11,493,967 22,402,780 9,500,000 - \$ 142,455,825 \$ 142,455,825 \$ 2,67,71,170 4,823,936 2,967,040 11,359,297 835,109 \$ 550,000 7,802 303,614 \$ 120,930,904 \$ 21,524,921 \$ 321,580,632 \$ 321,580,632 \$ 343,105,553 \$ 11,655,019 \$ (9,500,000) \$ 2,155,019 \$ 333,235,651	Projection \$ 57,645,385 15,078,565 1,369,691 22,548,674 930,086 - 1,486,677 11,493,967 22,402,780 9,500,000 - \$ 142,455,825 \$ 142,455,825 \$ 142,455,825 \$ 142,455,825 \$ 142,455,825 \$ 142,455,825 \$ 142,455,825 \$ 142,455,825 \$ 142,455,825 \$ 142,455,825 \$ 142,455,825 \$ 142,455,825 \$ 142,455,825 \$ 142,455,825 \$ 142,455,825 \$ 120,930,904 \$ 120,930,904 \$ 21,524,921 \$ 321,580,632 \$ 343,105,553 \$ 11,655,019 \$ (9,500,000) \$ 2,155,019 \$ 333,235,651	Projection Decision \$ 57,645,385 15,078,565 1,369,691 22,548,674 930,086 - 1,486,677 11,493,967 22,402,780 9,500,000 - \$ 142,455,825 \$ \$ 142,455,825 \$ \$ 142,455,825 \$ \$ 142,455,825 \$ \$ 142,455,825 \$ \$ 142,455,825 \$ \$ 142,455,825 \$ \$ 142,455,825 \$ \$ 142,455,825 \$ \$ 142,455,825 \$ \$ 142,455,825 \$ \$ 142,455,825 \$ \$ 142,455,825 \$ \$ 142,455,826 \$ \$ 142,455,827 \$ \$ 142,455,827 \$ \$ 142,455,827 \$ \$ 120,930,904 \$ \$ 120,930,904 \$ \$ 120,930,904 \$ \$ 11,655,019 \$ \$ 2,155,019 \$ \$ 2,155,019 \$ 333,235,651 \$	Projection Decision \$ 57,645,385 15,078,565 1,369,691 22,548,674 930,086 - - \$ 1,486,677 11,493,967 22,402,780 9,500,000 - \$ \$ 142,455,825 \$ - \$ \$ 142,455,825 \$ - \$ \$ 142,455,825 \$ - \$ \$ 142,455,825 \$ - \$ \$ 142,455,825 \$ - \$ \$ 142,455,825 \$ - \$ \$ 142,455,825 \$ - \$ \$ 142,455,825 \$ - \$ \$ 142,455,825 \$ - \$ \$ 142,455,826 \$ - \$ \$ 142,455,827 \$ \$ \$ \$ 120,930,904 \$ (4,484,103) \$ \$ 120,930,904 \$ (4,484,103) \$ \$ 11,655,019 \$ \$ \$ \$ 11,655,019 \$ \$ \$ \$ 2,155,019 \$ \$ \$

	KET 2			
Pay Go Monthly Premium for Actives	\$ 163.09	Claim a	nd Other Expense Trends	
Additional Retiree Premiums	\$ -	<u>Eligibility</u>	Medical	Drugs
Pay Go PEPM Subsidy for Retirees	\$ 553.27	Non-Medicare	5.5%	8.5%
		Capitations		-5.1%
		Administrative Expense		3.0%
Number of Net New Retirees	300	Pay Go Monthly Premiu	m	-0.4%

APPENDIX - BASELINE SCENARIO RHBT - MEDICARE AND NON-MEDICARE

WEST VIRGINIA RETIREE HEALTH BENEFIT TRUST FINANCIAL FORECAST FISCAL YEAR 2017

PERIOD 7/1/2016 - 6/30/2017

		7/1/2016 12/31/2016	t	1/1/2017 o 6/30/2017		TRUST Total
Revenues WV PEIA Pay Go Premiums Retiree Premiums - PPB Retiree Premiums - MCO Annual Required Contributions Non Par Premiums Life Insurance Investment Income Transfer from Premium Stabilization Reserve General Revenue	\$ \$	90,000,000 43,364,023 1,187,400 - 1,516,973 12,695,466 22,281,728 5,445,469 15,000,000 191,491,058	\$	90,000,000 43,873,428 1,187,400 - 1,516,973 12,695,466 22,281,728 5,554,531 15,000,000 192,109,526	\$	180,000,000 87,237,451 2,374,800 - 3,033,945 25,390,932 44,563,456 11,000,000 30,000,000 383,600,584
Program Expenses Non-Medicare Medical Claims Non-Medicare Prescription Drug Claims Medicare Medical Claims Medicare Prescription Drug Claims Non-Medicare Managed Care Capitations Humana MAPD Program Administration Life Insurance Retiree Assistance Program ACA Reinsurance Contributions ACA Comparative Effectiveness Research Fees Director's Discretionary Fund Total Expenses	\$	37,155,180 12,792,359 2,404,144 3,700,254 2,289,510 76,444,254 2,422,083 12,546,719 948,760 200,000 15,801 154,020 151,073,082	\$	39,264,359 14,902,725 1,174,073 1,833,389 2,289,510 82,412,607 2,422,083 12,546,719 948,760 - 15,801 154,020 157,964,043	\$	76,419,539 27,695,084 3,578,217 5,533,643 4,579,019 158,856,861 4,844,165 25,093,437 1,897,519 200,000 31,601 308,040 309,037,125
Fiscal Year Results	\$	40,417,976	\$	34,145,483	\$	74,563,459
Beginning Restricted Reserve Ending Restricted Reserve Beginning Premium Stabilization Reserve PSR Addition/(Drawdown) Ending Premium Stabilization Reserve Total Beginning Plan Reserve Total Ending Plan Reserve Accrued Actuarial Liability (AAL) Funded Status					\$ \$ \$ \$ \$ \$	714,717,516 789,280,975 15,439,335 (11,000,000) 4,439,335 730,156,851 793,720,311 3,899,600,000 20.4%

	1151	noo enin monto		
Pay Go Monthly Premium for Actives	\$ 195.71	Claim and C	Other Expense Trends	
Additional Retiree Premiums	\$ 4,380,722	Eligibility	Medical	Drugs
Pay Go PEPM Subsidy for Retirees	\$ 347.51	Non-Medicare	6.0%	9.0%
		Medicare	6.0%	9.0%
		Capitations		8.0%
		Administrative Expense		3.0%
Number of Net New Retirees	1,000	Pay Go Monthly Premium		23.8%

APPENDIX - BASELINE SCENARIO <u>RHBT - MEDICARE</u>

WEST VIRGINIA RETIREE HEALTH BENEFIT TRUST FINANCIAL FORECAST FISCAL YEAR 2017

PERIOD 7/1/2016 - 6/30/2017

Medicare	Baseline	Board	Ending
Retiree	Projection	Decision	Projection
Revenues WV PEIA Pay Go Premiums Employer Premiums - PPB Employer Premiums - MCO Retiree Premiums - PPB Retiree Premiums - MCO Annual Required Contributions Non Par Premiums Life Insurance Investment Income Transfer from Premium Stabilization Reserve General Revenue Transfer	\$ 111,629,489 7,923,748 405 37,254,110 158 - 1,591,869 13,322,267 23,217,589 9,000,000 17,119,827	2,684,686 11	\$ 111,629,489 7,923,748 405 39,938,796 169 - - 1,591,869 13,322,267 23,217,589 9,000,000 17,119,827
Total Revenue	\$ 221,059,463	\$ 2,684,697	\$ 223,744,160
Program Expenses Medicare Medical Claims Medicare Prescription Drug Claims Humana MAPD Program Administration Life Insurance Retiree Assistance Program ACA Reinsurance Contributions ACA Comparative Effectiveness Research Fees Director's Discretionary Fund Total Expenses	\$ 3,578,217 5,533,643 161,148,089 1,788,113 13,166,175 995,602 - 23,877 - \$ 186,233,716	\$ - (2,291,228) \$ (2,291,228)	\$ 3,578,217 5,533,643 158,856,861 1,788,113 13,166,175 995,602 - 23,877 - \$ 183,942,488
Fiscal Year Results	\$ 34,825,747		\$ 39,801,672
Beginning Restricted Reserve Ending Restricted Reserve Beginning Premium Stabilization Reserve PSR Addition/(Drawdown) Ending Premium Stabilization Reserve Total Beginning Plan Reserve Total Ending Plan Reserve Accrued Actuarial Liability (AAL) Funded Status	\$ 367,127,862 <u>\$ 401,953,608</u> \$ 13,284,316 \$ (9,000,000) <u>\$ 4,284,316</u> 380,412,178 <u>\$ 406,237,925</u> \$ 3,899,600,000 20.2%		\$ 367,127,862 <u>\$ 406,929,533</u> \$ 13,284,316 \$ (9,000,000) <u>\$ 4,284,316</u> 380,412,178 <u>\$ 411,213,850</u> \$ 3,899,600,000 20.4%

Pay Go Monthly Premium for Actives	\$	195.71	Claim a	and Other Expense Trends				
Additional Retiree Premiums	\$	2,684,697	<u>Eligibility</u>	Medical	Drugs			
Pay Go PEPM Subsidy for Retirees	\$	273.84	Medicare	6.0%	9.0%			
			Capitations		8.0%			
			Administrative Expense	:	3.0%			
Number of Net New Retirees		700	Pay Go Monthly Premiu	ım	23.8%			

APPENDIX - BASELINE SCENARIO RHBT - NON-MEDICARE

WEST VIRGINIA RETIREE HEALTH BENEFIT TRUST FINANCIAL FORECAST FISCAL YEAR 2017

PERIOD 7/1/2016 - 6/30/2017

Non-Medicare Retiree		Baseline Projection		Board Decision		Ending Projection
Revenues WV PEIA Pay Go Premiums Employer Premiums - PPB Employer Premiums - MCO Retiree Premiums - PPB Retiree Premiums - MCO Annual Required Contributions Non Par Premiums Life Insurance Investment Income Transfer from Premium Stabilization Reserve General Revenue Transfer	\$	68,370,511 15,126,184 1,374,016 22,619,884 933,023 - 1,442,077 12,068,665 21,345,868 2,000,000 12,880,173		1,628,839 67,186	\$	68,370,511 15,126,184 1,374,016 24,248,723 1,000,209 - 1,442,077 12,068,665 21,345,868 2,000,000 12,880,173
Total Revenue	\$	158,160,400	\$	1,696,025	\$	159,856,425
Program Expenses Non-Medicare Medical Claims Non-Medicare Prescription Drug Claims Non-Medicare Managed Care Capitations Administration Life Insurance Retiree Assistance Program ACA Reinsurance Contributions ACA Comparative Effectiveness Research Fees Director's Discretionary Fund Total Expenses	\$	76,419,539 27,695,084 4,579,019 3,056,051 11,927,262 901,917 200,000 7,724 308,040 125,094,636	\$ \$	-	\$	76,419,539 27,695,084 4,579,019 3,056,051 11,927,262 901,917 200,000 7,724 308,040 125,094,636
Fiscal Year Results	\$	33,065,765			\$	34,761,790
Beginning Restricted Reserve Ending Restricted Reserve Beginning Premium Stabilization Reserve PSR Addition/(Drawdown) Ending Premium Stabilization Reserve Total Beginning Plan Reserve Total Ending Plan Reserve	\$ \$ \$ \$	347,589,656 380,655,421 2,155,019 (2,000,000) 155,019 349,744,676 380,810,440			\$ \$ \$ \$	347,589,656 382,351,446 2,155,019 (2,000,000) 155,019 349,744,676 382,506,465
Accrued Actuarial Liability (AAL) Funded Status	\$	- N/A			\$	- N/A

Pay Go Monthly Premium for Actives	\$	195.71	Claim a	nd Other Expense Trends				
Additional Retiree Premiums	\$	1,696,025	<u>Eligibility</u>	Medical	Drugs			
Pay Go PEPM Subsidy for Retirees	\$	619.74	Non-Medicare	6.0%	9.0%			
			Capitations		8.0%			
			Administrative Expense		3.0%			
Number of Net New Retirees		300	Pay Go Monthly Premiu	Im	23.8%			

APPENDIX - BASELINE SCENARIO RHBT - MEDICARE AND NON-MEDICARE

WEST VIRGINIA RETIREE HEALTH BENEFIT TRUST FINANCIAL FORECAST FISCAL YEAR 2018

PERIOD 7/1/2017 - 6/30/2018

	to	7/1/2017 12/31/2017	1	1/1/2018 to 6/30/2018		TRUST Total
Revenues WV PEIA Pay Go Premiums Retiree Premiums - PPB Retiree Premiums - MCO Annual Required Contributions Non Par Premiums Life Insurance Investment Income Transfer from Premium Stabilization Reserve General Revenue Transfer Total Revenue	\$	97,500,000 52,906,805 1,341,535 - 1,471,464 13,330,240 24,230,105 2,196,520 15,000,000 207,976,668	\$	97,500,000 53,514,046 1,341,535 - 1,471,464 13,330,240 24,230,105 2,242,816 15,000,000 208,630,204	\$	195,000,000 106,420,851 2,683,070 - 2,942,927 26,660,479 48,460,209 4,439,335 30,000,000 416,606,872
I otal Revenue	\$	207,970,008	¢	208,630,204	2	410,000,872
Program Expenses Non-Medicare Medical Claims Non-Medicare Prescription Drug Claims Medicare Medical Claims Medicare Prescription Drug Claims Non-Medicare Managed Care Capitations Humana MAPD Program Administration Life Insurance Retiree Assistance Program ACA Reinsurance Contributions ACA Comparative Effectiveness Research Fees Director's Discretionary Fund	\$	40,118,300 14,197,075 2,552,115 4,039,016 2,472,671 84,661,233 2,494,745 13,174,055 1,024,660 - 16,204 156,187 164,906,260	\$	42,395,687 16,539,177 1,249,381 2,005,996 2,472,671 91,711,642 2,494,745 13,174,055 1,024,660 - 16,204 156,187	\$	82,513,987 30,736,252 3,801,496 6,045,012 4,945,341 176,372,874 4,989,490 26,348,109 2,049,320 - 32,408 312,374 338,146,663
Fiscal Year Results	\$	43,070,408	\$	35,389,800	\$	78,460,208
Beginning Restricted Reserve Ending Restricted Reserve					\$ \$	789,280,975 867,741,183
Beginning Premium Stabilization Reserve					\$	4,439,335
PSR Addition/(Drawdown)					\$	(4,439,335)
Ending Premium Stabilization Reserve					\$	
Total Beginning Plan Reserve					\$	793,720,311
Total Ending Plan Reserve					\$	867,741,183
Accrued Actuarial Liability (AAL)					\$	4,044,600,000
Funded Status						21.5%

	1151	needen in the the		
Pay Go Monthly Premium for Actives	\$ 212.02	Claim and O	ther Expense Trends	
Additional Retiree Premiums	\$ 18,937,242	Eligibility	Medical	Drugs
Pay Go PEPM Subsidy for Retirees	\$ 367.86	Non-Medicare	6.5%	9.5%
		Medicare	6.5%	9.5%
		Capitations		8.0%
		Administrative Expense		3.0%
Number of Net New Retirees	1,000	Pay Go Monthly Premium		10.5%

APPENDIX - BASELINE SCENARIO <u>RHBT - MEDICARE</u>

WEST VIRGINIA RETIREE HEALTH BENEFIT TRUST FINANCIAL FORECAST FISCAL YEAR 2018

PERIOD 7/1/2017 - 6/30/2018

Medicare	Baseline	Board	Ending
Retiree	Projection	Decision	Projection
Revenues WV PEIA Pay Go Premiums Employer Premiums - PPB Employer Premiums - MCO Retiree Premiums - PPB Retiree Premiums - MCO Annual Required Contributions Non Par Premiums Life Insurance Investment Income Transfer from Premium Stabilization Reserve General Revenue Transfer	\$ 121,991,034 7,952,031 406 40,142,724 170 - 1,544,113 13,988,380 25,106,462 4,284,316 17,305,078	11,602,249 49	\$ 121,991,034 7,952,031 406 51,744,973 219 - 1,544,113 13,988,380 25,106,462 4,284,316 17,305,078
Total Revenue	\$ 232,314,715	\$ 11,602,298	\$ 243,917,013
Program Expenses Medicare Medical Claims Medicare Prescription Drug Claims Humana MAPD Program Administration Life Insurance Retiree Assistance Program ACA Reinsurance Contributions ACA Comparative Effectiveness Research Fees Director's Discretionary Fund Total Expenses	\$ 3,801,496 6,045,012 176,372,874 1,841,757 13,824,484 1,075,250 - 24,761 - \$ 202,985,634	\$ - - \$ -	\$ 3,801,496 6,045,012 176,372,874 1,841,757 13,824,484 1,075,250 - 24,761 - \$ 202,985,634
Fiscal Year Results	\$ 29,329,080		\$ 40,931,378
Beginning Restricted Reserve Ending Restricted Reserve Beginning Premium Stabilization Reserve PSR Addition/(Drawdown) Ending Premium Stabilization Reserve Total Beginning Plan Reserve	\$ 406,929,533 <u>\$ 436,258,613</u> \$ 4,284,316 \$ (4,284,316) <u>\$ -</u> 411,213,850		\$ 406,929,533 <u>\$ 447,860,911</u> \$ 4,284,316 \$ (4,284,316) <u>\$ -</u> 411,213,850
Total Ending Plan Reserve	\$ 436,258,613		\$ 447,860,911
Accrued Actuarial Liability (AAL) Funded Status	\$ 4,044,600,000 21.0%		\$ 4,044,600,000 21.5%

Pay Go Monthly Premium for Actives	\$	212.02	Claim a	nd Other Expense Trends			
Additional Retiree Premiums	\$	11,602,298	<u>Eligibility</u>	Medical	Drugs		
Pay Go PEPM Subsidy for Retirees	\$	294.91	Medicare	6.5%	9.5%		
			Capitations		8.0%		
			Administrative Expense		3.0%		
Number of Net New Retirees		700	Pay Go Monthly Premiu	Im	10.5%		

APPENDIX - BASELINE SCENARIO RHBT - NON-MEDICARE

WEST VIRGINIA RETIREE HEALTH BENEFIT TRUST FINANCIAL FORECAST FISCAL YEAR 2018

PERIOD 7/1/2017 - 6/30/2018

Non-Medicare Retiree		Baseline Projection	Bo Decis	ard ion		Ending Projection
Revenues WV PEIA Pay Go Premiums Employer Premiums - PPB Employer Premiums - MCO Retiree Premiums - MCO Annual Required Contributions Non Par Premiums Life Insurance Investment Income Transfer from Premium Stabilization Reserve General Revenue Transfer	\$	73,008,966 15,228,845 1,383,342 24,450,624 1,008,537 - 1,398,814 12,672,099 23,353,747 155,019 12,694,922	7,044, 290,:	378	\$	73,008,966 15,228,845 1,383,342 31,495,002 1,299,103 - 1,398,814 12,672,099 23,353,747 155,019 12,694,922
Total Revenue	\$	165,354,915	\$ 7,334,9	944	\$	172,689,859
Program Expenses Non-Medicare Medical Claims Non-Medicare Prescription Drug Claims Non-Medicare Managed Care Capitations Administration Life Insurance Retiree Assistance Program ACA Reinsurance Contributions ACA Comparative Effectiveness Research Fees Director's Discretionary Fund Total Expenses	\$	82,513,987 30,736,252 4,945,341 3,147,733 12,523,625 974,071 - 7,647 312,374 135,161,030	\$	-	\$	82,513,987 30,736,252 4,945,341 3,147,733 12,523,625 974,071 - 7,647 312,374 135,161,030
Fiscal Year Results	\$	30,193,885			\$	37,528,829
Beginning Restricted Reserve Ending Restricted Reserve Beginning Premium Stabilization Reserve PSR Addition/(Drawdown) Ending Premium Stabilization Reserve Total Beginning Plan Reserve Total Ending Plan Reserve	\$ \$ \$ \$	382,351,446 <u>412,545,331</u> 155,019 (155,019) <u>-</u> 382,506,465 <u>412,545,331</u>			\$ \$ \$ \$ \$	382,351,446 <u>419,880,275</u> 155,019 (155,019) <u>-</u> 382,506,465 <u>419,880,275</u>
Accrued Actuarial Liability (AAL) Funded Status	\$	- N/A			\$	- N/A

Pay Go Monthly Premium for Actives	\$	212.02	Claim a	nd Other Expense Trends			
Additional Retiree Premiums	\$	7,334,944	Eligibility	Medical	Drugs		
Pay Go PEPM Subsidy for Retirees	\$	627.02	Non-Medicare	6.5%	9.5%		
			Capitations		8.0%		
			Administrative Expense		3.0%		
Number of Net New Retirees		300	Pay Go Monthly Premiu	m	10.5%		

APPENDIX - BASELINE SCENARIO RHBT - MEDICARE AND NON-MEDICARE

WEST VIRGINIA RETIREE HEALTH BENEFIT TRUST FINANCIAL FORECAST FISCAL YEAR 2019

PERIOD 7/1/2018 - 6/30/2019

	IIBI	noo chini morto		
Pay Go Monthly Premium for Actives	\$ 228.33	Claim and Claim	Other Expense Trends	
Additional Retiree Premiums	\$ 21,377,582	<u>Eligibility</u>	Medical	Drugs
Pay Go PEPM Subsidy for Retirees	\$ 387.30	Non-Medicare	7.0%	10.0%
		Medicare	7.0%	10.0%
		Capitations		8.0%
		Administrative Expense		3.0%
Number of Net New Retirees	1,000	Pay Go Monthly Premium		7.7%

APPENDIX - BASELINE SCENARIO <u>RHBT - MEDICARE</u>

WEST VIRGINIA RETIREE HEALTH BENEFIT TRUST FINANCIAL FORECAST FISCAL YEAR 2019

PERIOD 7/1/2018 - 6/30/2019

Medicare	Τ	Baseline		Board		Ending
Retiree		Projection		Decision		Projection
Revenues WV PEIA Pay Go Premiums Employer Premiums - PPB Employer Premiums - MCO Retiree Premiums - PPB Retiree Premiums - MCO Annual Required Contributions Non Par Premiums Life Insurance Investment Income Transfer from Premium Stabilization Reserve General Revenue Transfer	\$	132,527,078 7,953,081 407 52,022,081 221 - 1,497,789 14,687,799 27,351,163 - 17,452,630	1	3,084,606 55	\$	132,527,078 7,953,081 407 65,106,687 276 - 1,497,789 14,687,799 27,351,163 - 17,452,630
Total Revenue	\$	253,492,249	\$ 1	3,084,661	\$	266,576,910
Program Expenses Medicare Medical Claims Medicare Prescription Drug Claims Humana MAPD Program Administration Life Insurance Retiree Assistance Program ACA Reinsurance Contributions ACA Comparative Effectiveness Research Fees Director's Discretionary Fund Total Expenses	\$	4,057,723 6,633,872 196,763,954 1,897,010 14,515,708 1,161,270 - 25,678 - 225,055,215	\$	-	\$	4,057,723 6,633,872 196,763,954 1,897,010 14,515,708 1,161,270 - 25,678 - 225,055,215
Fiscal Year Results	\$	28,437,034			\$	41,521,695
Beginning Restricted Reserve Ending Restricted Reserve Beginning Premium Stabilization Reserve PSR Addition/(Drawdown) Ending Premium Stabilization Reserve Total Beginning Plan Reserve Total Ending Plan Reserve Accrued Actuarial Liability (AAL)	\$ \$ \$ \$ \$	447,860,911 476,297,945 - - - 447,860,911 476,297,945 4,181,000,000			\$ \$ \$ \$ \$ \$	447,860,911 489,382,606 - - - 447,860,911 489,382,606 4,181,000,000
Funded Status		22.2%				22.7%

	KE1.			
Pay Go Monthly Premium for Actives	\$ 228.33	Claim a	nd Other Expense Trends	
Additional Retiree Premiums	\$ 13,084,661	<u>Eligibility</u>	Medical	Drugs
Pay Go PEPM Subsidy for Retirees	\$ 315.80	Medicare	7.0%	10.0%
		Capitations		8.0%
		Administrative Expense		3.0%
Number of Net New Retirees	700	Pay Go Monthly Premiu	m	7.7%

APPENDIX - BASELINE SCENARIO RHBT - NON-MEDICARE

WEST VIRGINIA RETIREE HEALTH BENEFIT TRUST FINANCIAL FORECAST FISCAL YEAR 2019

PERIOD 7/1/2018 - 6/30/2019

Non-Medicare Retiree		Baseline Projection	Board Decision		Ending Projection
Revenues WV PEIA Pay Go Premiums Employer Premiums - PPB Employer Premiums - PPB Retiree Premiums - MCO Annual Required Contributions Non Par Premiums Life Insurance Investment Income Transfer from Premium Stabilization Reserve General Revenue Transfer	\$	77,472,922 15,280,358 1,388,021 31,765,635 1,310,266 - 1,356,850 13,305,704 25,642,367 - 12,547,370	7,964,406 328,515	\$	77,472,922 15,280,358 1,388,021 39,730,041 1,638,781 - 1,356,850 13,305,704 25,642,367 - 12,547,370
Total Revenue	\$	180,069,493	\$ 8,292,921	\$	188,362,414
Program Expenses Non-Medicare Medical Claims Non-Medicare Prescription Drug Claims Non-Medicare Managed Care Capitations Administration Life Insurance Retiree Assistance Program ACA Reinsurance Contributions ACA Comparative Effectiveness Research Fees Director's Discretionary Fund Total Expenses	\$ \$	89,513,807 34,267,508 5,340,968 3,242,165 13,149,806 1,051,996 - 7,570 316,758 146,890,578	\$ -	\$	89,513,807 34,267,508 5,340,968 3,242,165 13,149,806 1,051,996 - 7,570 316,758 146,890,578
Fiscal Year Results	\$	33,178,915		\$	41,471,836
Beginning Restricted Reserve Ending Restricted Reserve Beginning Premium Stabilization Reserve PSR Addition/(Drawdown) Ending Premium Stabilization Reserve Total Beginning Plan Reserve Total Ending Plan Reserve Accrued Actuarial Liability (AAL) Funded Status	\$ \$ \$ \$ \$ \$	419,880,275 453,059,190 - - - 419,880,275 453,059,190 - N/A		\$ \$ \$ \$ \$	419,880,275 461,352,111 - - 419,880,275 461,352,111 - N/A

Pay Go Monthly Premium for Actives	\$ 228.33	Claim a	nd Other Expense Trends	
Additional Retiree Premiums	\$ 8,292,921	<u>Eligibility</u>	Medical	Drugs
Pay Go PEPM Subsidy for Retirees	\$ 632.12	Non-Medicare	7.0%	10.0%
		Capitations		8.0%
		Administrative Expense		3.0%
Number of Net New Retirees	300	Pay Go Monthly Premiur	m	7.7%

APPENDIX - BASELINE SCENARIO RHBT - MEDICARE AND NON-MEDICARE

WEST VIRGINIA RETIREE HEALTH BENEFIT TRUST FINANCIAL FORECAST FISCAL YEAR 2020

PERIOD 7/1/2019 - 6/30/2020

to	7/1/2019 12/31/2019	t	1/1/2020 0 6/30/2020		TRUST Total
\$	110,000,000 77,259,852 1,731,387 - 1,384,500 14,696,589 29,037,669 - 15,000,000 249,109,997	\$	110,000,000 78,107,681 1,731,387 - 1,384,500 14,696,589 29,037,669 - 15,000,000 249,957,826	\$	220,000,000 155,367,533 3,462,773 - 2,769,000 29,393,178 58,075,339 - 30,000,000 499,067,823
\$ \$	47,434,815 17,727,050 2,916,708 4,878,761 2,884,123 105,348,036 2,646,675 14,524,395 1,195,164 - 160,596 199,716,322	\$	50,127,535 20,651,495 1,434,808 2,434,515 2,884,123 115,216,857 2,646,675 14,524,395 1,195,164 - 160,596 211,276,162	\$	97,562,350 38,378,545 4,351,516 7,313,276 5,768,245 220,564,893 5,293,350 29,048,790 2,390,327 - 321,192 410,992,484
\$	49,393,675	\$	38,681,664	\$	88,075,339
				\$ \$ \$ \$	950,734,712 1,038,810,051 - - - 950,734,712 1,038,810,051
	\$ \$ \$	to 12/31/2019 \$ 110,000,000 77,259,852 1,731,387 - 1,384,500 14,696,589 29,037,669 29,037,000 \$ 249,109,997 \$ 47,434,815 17,727,050 2,916,708 4,878,761 2,884,123 105,348,036 2,646,675 14,524,395 1,195,164 - - 160,596 \$ 199,716,322	to 12/31/2019 to \$ 110,000,000 \$ 77,259,852 1,731,387 - - 1,384,500 14,696,589 29,037,669 - 15,000,000 \$ \$ 249,109,997 \$ \$ 47,434,815 \$ 17,727,050 2,916,708 4,878,761 2,884,123 105,348,036 2,646,675 14,524,395 1,195,164 - - 160,596 \$ \$ 199,716,322 \$	to 12/31/2019to 6/30/2020\$110,000,000\$77,259,85278,107,6811,731,3871,731,3871,731,3871,731,3871,384,5001,384,50014,696,58914,696,58929,037,66929,037,6699249,109,997\$249,109,997\$249,109,997\$249,107,05020,651,4952,916,7081,434,8084,878,7612,434,5152,884,1232,884,123105,348,036115,216,8572,646,6752,646,67514,524,39514,524,3951,195,1641,195,164160,596160,596\$199,716,322\$211,276,162	to 12/31/2019 to 6/30/2020 \$ 110,000,000 77,259,852 \$ 110,000,000 78,107,681 \$ 1,334,500 1,384,500 1,384,500 1,384,500 \$ 1,384,500 1,384,500 1,384,500 \$ \$ 1,384,500 1,384,500 1,4,696,589 \$ \$ 1,384,500 1,384,500 \$ \$ \$ 1,384,500 1,384,500 \$ \$ \$ 1,5,000,000 15,000,000 \$ \$ \$ \$ 249,109,997 \$ 249,957,826 \$ \$ 249,109,997 \$ 249,957,826 \$ \$ 249,109,997 \$ 249,957,826 \$ \$ 249,109,997 \$ 249,957,826 \$ \$ 249,109,997 \$ 249,957,826 \$ \$ 2,916,708 1,434,808 \$ \$ \$ 2,84,123 2,884,123 2,884,123 \$ \$ 1,95,164

	IIBI	noo en ni i i o no		
Pay Go Monthly Premium for Actives	\$ 239.20	Claim and O	ther Expense Trends	
Additional Retiree Premiums	\$ 26,987,410	Eligibility	Medical	Drugs
Pay Go PEPM Subsidy for Retirees	\$ 396.87	Non-Medicare	7.5%	10.5%
		Medicare	7.5%	10.5%
		Capitations		8.0%
		Administrative Expense		3.0%
Number of Net New Retirees	1,000	Pay Go Monthly Premium		4.8%

APPENDIX - BASELINE SCENARIO <u>RHBT - MEDICARE</u>

WEST VIRGINIA RETIREE HEALTH BENEFIT TRUST FINANCIAL FORECAST FISCAL YEAR 2020

PERIOD 7/1/2019 - 6/30/2020

Medicare	Baseline		Ending
Retiree	Projection	Decision	Projection
Revenues WV PEIA Pay Go Premiums Employer Premiums - PPB Employer Premiums - MCO Retiree Premiums - MPB Retiree Premiums - MCO Annual Required Contributions Non Par Premiums Life Insurance Investment Income Transfer from Premium Stabilization Reserve General Revenue Transfer	\$ 140,284,877 7,958,927 407 65,424,514 277 - 1,452,855 15,422,189 29,893,786 - 17,587,754	16,501,710 70	\$ 140,284,877 7,958,927 407 81,926,224 347 - 1,452,855 15,422,189 29,893,786 - 17,587,754
Total Revenue	\$ 278,025,587	\$ 16,501,780	\$ 294,527,367
Program Expenses Medicare Medical Claims Medicare Prescription Drug Claims Humana MAPD Program Administration Life Insurance Retiree Assistance Program ACA Reinsurance Contributions ACA Comparative Effectiveness Research Fees Director's Discretionary Fund Total Expenses	 \$ 4,351,516 7,313,276 220,564,893 1,953,920 15,241,493 1,254,171 - - - \$ 250,679,269 	\$ - - \$ -	 \$ 4,351,516 7,313,276 220,564,893 1,953,920 15,241,493 1,254,171 - - - \$ 250,679,269
Fiscal Year Results	\$ 27,346,318		\$ 43,848,098
Beginning Restricted Reserve Ending Restricted Reserve Beginning Premium Stabilization Reserve PSR Addition/(Drawdown)	\$ 489,382,606 <u>\$ 516,728,924</u> \$ - \$ -		\$ 489,382,606 <u>\$ 533,230,704</u> \$ -
	φ -		φ -
Ending Premium Stabilization Reserve	<u>\$</u>		<u> </u>
Total Beginning Plan Reserve	489,382,606		489,382,606
Total Ending Plan Reserve	\$ 516,728,924		\$ 533,230,704
Accrued Actuarial Liability (AAL)	\$ 4,297,300,000		\$ 4,297,300,000
Funded Status	23.5%		24.2%

	ILLI .			
Pay Go Monthly Premium for Actives	\$ 239.20	Claim an	d Other Expense Trends	
Additional Retiree Premiums	\$ 16,501,780	<u>Eligibility</u>	Medical	Drugs
Pay Go PEPM Subsidy for Retirees	\$ 329.58	Medicare	7.5%	10.5%
		Capitations		8.0%
		Administrative Expense		3.0%
Number of Net New Retirees	700	Pay Go Monthly Premiun	n	4.8%

APPENDIX - BASELINE SCENARIO RHBT - NON-MEDICARE

WEST VIRGINIA RETIREE HEALTH BENEFIT TRUST FINANCIAL FORECAST FISCAL YEAR 2020

PERIOD 7/1/2019 - 6/30/2020

Non-Medicare Retiree		Baseline Projection	Board Decision		Ending Projection
Revenues WV PEIA Pay Go Premiums Employer Premiums - PPB Employer Premiums - PPB Retiree Premiums - MCO Annual Required Contributions Non Par Premiums Life Insurance Investment Income Transfer from Premium Stabilization Reserve General Revenue Transfer	\$	79,715,123 15,346,287 1,394,010 40,065,842 1,652,632 - 1,316,144 13,970,989 28,181,552 - 12,412,246	10,070,253 415,377	\$	79,715,123 15,346,287 1,394,010 50,136,095 2,068,009 - 1,316,144 13,970,989 28,181,552 - 12,412,246
Total Revenue	\$	194,054,824	\$ 10,485,630	\$	204,540,454
Program Expenses Non-Medicare Medical Claims Non-Medicare Prescription Drug Claims Non-Medicare Managed Care Capitations Administration Life Insurance Retiree Assistance Program ACA Reinsurance Contributions ACA Comparative Effectiveness Research Fees Director's Discretionary Fund	\$	97,562,350 38,378,545 5,768,245 3,339,430 13,807,296 1,136,156 - 321,192 160,313,214	\$ - -	\$	97,562,350 38,378,545 5,768,245 3,339,430 13,807,296 1,136,156 - 321,192 160,313,214
Fiscal Year Results	\$	33,741,610		\$	44,227,240
Beginning Restricted Reserve Ending Restricted Reserve	\$ <u>\$</u>	461,352,111 495,093,721		\$ \$	461,352,111 505,579,351
Beginning Premium Stabilization Reserve	\$	-		\$	-
PSR Addition/(Drawdown)	\$	-		\$	-
Ending Premium Stabilization Reserve	\$	-		\$	-
Total Beginning Plan Reserve		461,352,111			461,352,111
Total Ending Plan Reserve	\$	495,093,721		\$	505,579,351
Accrued Actuarial Liability (AAL)	\$	-		\$	-
Funded Status		N/A			N/A

	ing i	ibbenii iionb		
Pay Go Monthly Premium for Actives	\$ 239.20	Claim ar	nd Other Expense Trends	
Additional Retiree Premiums	\$ 10,485,630	<u>Eligibility</u>	Medical	Drugs
Pay Go PEPM Subsidy for Retirees	\$ 619.46	Non-Medicare	7.5%	10.5%
		Capitations		8.0%
		Administrative Expense		3.0%
Number of Net New Retirees	300	Pay Go Monthly Premiur	m	4.8%

Attachment - Trust Fund Historical Monthly Medical and Drug Trends FY 2015 to FY 2016

Fiscal Year 2015 Exposure Jui-14 Aug-14 Sep-14 Oct-14 Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 NonMed_NonDrug 20,65 2,361 2,064 2,042 20,263 20,330 20,206 20,213 19,976 19,802 19,579 Med_NonDrug 19,191 19,328 19,385 19,146 18,924 18,777 18,838 18,723 18,752 18,512 18,352 18,142 Med_Drug 2,151 2,459 2,712 2,982 3,238 3,512 883 1,092 1,300 1,497 1,699 1,919 NonMed_NonDrug 176,95 190,06 \$305,16 \$237,02 \$266,54 \$297,12 \$235,66 \$201,02 \$304,86 \$309,47 \$339,90 Med_NonDrug 95,51 116,94 118,12 119,13 117,43 132,31 128,44 182,92 17,21 280,44 142,459 224,44 199,12							004 E						1
Jul-14 Aug-14 Sep-14 Oct-14 Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 NonMed_NonDrug 20,066 2,361 2,060 20,263 20,330 20,203 19,976 19,976 19,976 19,976 19,976 19,976 19,802 19,579 Med_NonDrug 2,065 2,361 2,604 2,863 3,108 3,371 848 1,048 1,248 1,437 1,832 18,512 18,352 18,122 18,352 18,122 18,352 18,122 18,352 18,122 18,352 18,142 Med_Drug 2,151 2,459 2,712 2,982 3,238 3,212 883 1,092 1,300 1,497 1,899 1,919 Med_Drug 16.95 19,08 19,065 174,10 130,11 148,73 294,24 186,29 217,27 280,71 280,61 213,76 NonMed_Drug 20,10 234,16 249,99 232,60	Expective					FISCAL TE	ear 2015						
NonMed_NonDrug 20,714 20,861 20,922 20,660 20,420 20,233 20,206 20,231 19,976 19,802 19,876 Med_NonDrug 2,065 2,361 2,604 2,863 3,108 3,371 848 1,048 1,248 1,437 1,631 1,842 Med_Drug 2,151 2,459 2,712 2,982 3,238 3,512 883 1,092 1,300 1,497 1,699 1,919 NonMed_Drug 2,151 2,459 2,712 2,982 3,238 3,512 883 1,092 1,300 1,497 1,699 1,919 NonMed_Drug 176.95 190.08 190.56 174.10 130.11 148.73 294.24 188.29 217.21 260.77 209.61 213.76 NonMed_Drug 95.51 116.94 118.12 119.13 117.43 132.31 128.24 118.42 127.40 128.14 425.43 Total \$725.23 \$759.96 \$808.37	Exposure	1.1.1.4.4	Aug 14	Son 14	Oct 14	Nov 14	Dec 14	lon 15	Eab 15	Mor 15	Apr 15	Mov 15	lun 15
Med_NonDrug 2,065 2,361 2,604 2,863 3,108 3,371 848 1,048 1,248 1,437 1,631 1,842 NonMed_Drug 19,191 19,328 19,385 19,146 18,924 18,777 18,838 18,723 18,752 18,552 18,512 18,352 18,142 Med_Drug 2,151 2,459 2,712 2,982 3,238 3,512 883 1,092 1,300 1,497 1,699 1,919 NonMed_Drug \$232.67 \$271.878 \$\$250.60 \$305.16 \$237.02 \$266.54 \$297.27 \$235.69 \$291.02 \$304.86 \$309.47 \$339.90 Med_NonDrug 16.94 118.12 119.13 117.43 132.31 128.24 119.12 128.48 127.40 128.41 142.48 127.40 128.41 142.44 142.41 142.41 142.41 142.41 142.41 142.41 142.41 142.41 142.41 142.41 142.41 142.41 142.44 142.44 14.44 14.44 14.44 14.44 14.44 14.44 14	NonMod NonDrug												
NonMed_Drug 19,191 19,328 19,385 19,146 18,824 18,777 18,838 18,723 18,752 18,512 18,352 18,142 Med_Drug 2,151 2,459 2,712 2,982 3,238 3,512 883 1,092 1,300 1,497 1,699 1,919 NonMed_NonDrug \$232.67 \$218.78 \$250.60 \$305.16 \$237.02 \$266.54 \$297.27 \$235.69 \$291.02 \$304.86 \$309.47 \$339.90 Med_NonDrug 16.94 118.12 111.13 117.43 132.231 128.24 118.27 128.44 142.59 Med_Drug 92.010 234.16 249.09 232.60 218.72 263.72 253.70 230.35 250.32 243.49 235.46 252.43 Total \$772.53 \$759.96 \$808.37 \$830.99 \$703.28 \$811.28 \$973.45 \$867.03 \$936.52 \$882.68 \$946.68 Change From Prior Year - Month to Month Analysis NonMed_Drug 2.3% <th></th> <th></th> <th></th> <th></th> <th>,</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>					,								
Med_Drug 2,151 2,459 2,712 2,982 3,238 3,512 883 1,092 1,300 1,497 1,699 1,919 NonMed_NonDrug \$232.67 \$221.078 \$220.60 \$305.16 \$227.02 \$266.54 \$297.7 \$235.69 \$291.02 \$304.86 \$309.47 \$339.90 Med_NonDrug 95.51 116.94 118.12 119.13 117.43 132.31 128.24 119.12 128.48 127.40 128.14 142.59 Med_Drug 202.10 234.16 249.09 232.60 218.72 263.72 253.70 230.35 250.32 243.49 235.46 \$948.68 Change From Prior Year - Month to Month Analysis NomMed_Drug -3.6% 6.8% 23.1% -14.4% 17.2% 3.9% -6.7% 13.6% 5.5% 19.2% 21.8% Med_NonDrug -22.9% -10.0% -2.3% -5.9% 53.5% 40.3% -13.6% 5.5% 19.2% 21.8% MonMed_NonDrug 2.2% <th></th> <th>,</th> <th></th> <th>,</th> <th>,</th> <th>,</th> <th></th> <th></th> <th>,</th> <th></th> <th></th> <th></th> <th></th>		,		,	,	,			,				
Jul-14 Aug-14 Sep-14 Oct-14 Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 NonMed_NonDrug \$232.67 \$218.78 \$250.60 \$305.16 \$237.02 \$266.54 \$297.07 \$235.69 \$291.02 \$304.86 \$309.47 \$339.90 Med_NonDrug 176.95 190.08 190.56 174.10 130.11 148.73 294.24 188.29 217.21 260.77 209.61 213.76 NonMed_Drug 220.10 234.16 249.09 222.60 218.72 263.72 230.35 \$250.32 243.49 235.46 \$22.43 Total \$725.23 \$759.96 \$808.37 \$830.99 \$703.28 \$811.26 \$973.45 \$773.45 \$887.03 \$936.52 \$882.68 \$948.68 Change From Prior Year - Month to Month Analysis 3.9% -6.7% 13.6% 5.5% 19.2% 21.8% NonMed_Drug 22.9% -10.0% -2.3%	- •				,	,	,	,	,	,	,	,	,
NonMed_NonDrug \$232.67 \$218.78 \$250.60 \$305.16 \$237.02 \$266.54 \$297.27 \$235.69 \$291.02 \$304.86 \$309.47 \$339.90 Med_NonDrug 176.95 190.08 190.56 174.10 130.11 148.73 294.24 188.29 217.21 260.77 209.61 213.76 NonMed_Drug 95.51 116.94 118.12 119.13 117.43 132.31 128.24 119.12 128.48 127.40 128.14 142.59 Med_Drug 220.10 234.16 249.09 232.60 280.72 253.70 230.35 250.22 243.49 235.46 252.43 Total \$775.23 \$759.96 \$808.37 \$830.99 \$703.28 \$811.28 \$973.45 \$773.45 \$887.03 \$936.52 \$882.68 \$948.68 Change From Prior Year - Month to Month Analysis 17.8% -23.2% -5.9% 53.5% -40.3% -13.6% 5.5% 19.2% 21.8% Med_NonDrug 2.9.4% <th>Med_Drug</th> <th>2,151</th> <th>2,459</th> <th>2,712</th> <th>2,982</th> <th>3,238</th> <th>3,512</th> <th>883</th> <th>1,092</th> <th>1,300</th> <th>1,497</th> <th>1,699</th> <th>1,919</th>	Med_Drug	2,151	2,459	2,712	2,982	3,238	3,512	883	1,092	1,300	1,497	1,699	1,919
Med_NonDrug 176.95 190.08 190.56 174.10 130.11 148.73 294.24 188.29 217.21 260.77 209.61 213.76 NonMed_Drug 95.51 116.94 118.12 119.13 117.43 132.31 128.24 119.12 128.48 127.40 128.14 142.59 Med_Drug 220.10 234.16 249.09 232.60 218.72 263.72 253.70 230.35 250.32 243.49 235.66 \$\$24.33 Total \$772.52 \$759.96 \$808.37 \$830.99 \$703.28 \$\$17.28 \$\$773.45 \$\$87.03 \$\$936.52 \$\$82.68 \$\$94.68 Change From Prior Year - Month to Month Analysis . <th></th> <td></td>													
NonMed_Drug 95.51 116.94 118.12 119.13 117.43 132.31 128.24 119.12 128.48 127.40 128.14 142.59 Med_Drug 220.10 234.16 249.09 232.60 218.72 263.72 253.70 230.35 250.32 243.49 235.46 252.43 Total \$7725.23 \$759.96 \$808.37 \$830.99 \$703.28 \$811.28 \$973.45 \$773.45 \$887.03 \$936.52 \$882.68 \$948.68 Change From Prior Year - Month to Month Analysis					-	-		-	-		-	-	-
Med_Drug 220.10 234.16 249.09 232.60 218.72 263.72 253.70 230.35 250.32 243.49 235.46 252.43 Total \$7725.23 \$759.96 \$808.37 \$830.99 \$7703.28 \$811.28 \$973.45 \$773.45 \$887.03 \$936.52 \$882.68 \$948.68 Change From Prior Year - Month to Month Analysis \$25.76 \$23.70 \$393.652 \$40.38 \$393.652 \$882.68 \$948.68 Med_NonDrug 2.8% -3.6% 6.8% 23.1% -14.4% 17.2% 3.9% -6.7% 13.6% 5.5% 19.2% 21.8% NonMed_Drug 8.0% 11.5% 12.0% -1.1% 8.5% 5.7% 3.6% 10.6% 6.7% -0.4% 2.8% 2.0% Med_Drug 2.1% -1.1% 8.5% 5.7% 3.6% 10.6% 7.7% 5.0%													
Total \$725.23 \$759.96 \$808.37 \$830.99 \$703.28 \$811.28 \$973.45 \$773.45 \$887.03 \$936.52 \$882.68 \$948.68 Change From Prior Year - Month to Month Analysis NonMed_NonDrug 2.8% -3.6% 6.8% 23.1% -14.4% 17.2% 3.9% -6.7% 13.6% 5.5% 19.2% 21.8% Med_NonDrug -22.9% -10.0% -2.3% -17.8% -23.2% -5.9% 53.5% -40.3% -13.6% 17.0% 9.4% -4.5% NonMed_Drug 8.0% 11.5% 12.0% -1.1% 8.5% 5.7% 3.6% 10.6% 6.7% -0.4% 2.8% 2.0% Med_Drug 29.4% 3.2% 34.3% 5.4% 5.6% 1.0% 74.1% 2.4% 10.6% 7.9% 5.0% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% <td< td=""><th>- •</th><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	- •												
Change From Prior Year - Month to Month Analysis NonMed_NonDrug 2.8% -3.6% 6.8% 23.1% -14.4% 17.2% 3.9% -6.7% 13.6% 5.5% 19.2% 21.8% Med_NonDrug -22.9% -10.0% -2.3% -17.8% -23.2% -5.9% 53.5% -40.3% -13.6% 17.0% 9.4% -4.5% NonMed_Drug 8.0% 11.5% 12.0% -1.1% 8.5% 5.7% 3.6% 10.6% 6.7% -0.4% 2.8% 2.0% Med_Drug 29.4% 3.2% 34.3% 5.4% 5.6% 1.0% 7.41% 2.4% 10.6% 7.9% 5.0% 0.5%	Med_Drug												
NonMed_NonDrug 2.8% -3.6% 6.8% 23.1% -14.4% 17.2% 3.9% -6.7% 13.6% 5.5% 19.2% 21.8% Med_NonDrug -22.9% -10.0% -2.3% -17.8% -23.2% -5.9% 53.5% -40.3% -13.6% 17.0% 9.4% -4.5% NonMed_Drug 8.0% 11.5% 12.0% -1.1% 8.5% 5.7% 3.6% 10.6% 6.7% -0.4% 2.8% 2.0% Med_Drug 29.4% 3.2% 34.3% 5.4% 5.6% 10.0% 74.1% 2.4% 10.6% 7.9% 5.0% 0.5% Total 1.5% -1.3% 12.2% 3.8% -7.7% 5.1% 30.3% -14.1% 3.8% 8.2% 10.3% 6.1% Change From Prior Year - Quarter to Quarter Analysis 7.5% 3.7% 15.3% 7.2% 7.5% 3.7% 15.3% 7.2% 7.5% 3.7% 15.3% 15.5% 15.5% 1.5% 1.5% 3.8% <td< td=""><th>Total</th><td>\$725.23</td><td>\$759.96</td><td>\$808.37</td><td>\$830.99</td><td>\$703.28</td><td>\$811.28</td><td>\$973.45</td><td>\$773.45</td><td>\$887.03</td><td>\$936.52</td><td>\$882.68</td><td>\$948.68</td></td<>	Total	\$725.23	\$759.96	\$808.37	\$830.99	\$703.28	\$811.28	\$973.45	\$773.45	\$887.03	\$936.52	\$882.68	\$948.68
Med_NonDrug -22.9% -10.0% -2.3% -17.8% -23.2% -5.9% 53.5% -40.3% -13.6% 17.0% 9.4% -4.5% NonMed_Drug 8.0% 11.5% 12.0% -1.1% 8.5% 5.7% 3.6% 10.6% 6.7% -0.4% 2.8% 2.0% Med_Drug 29.4% 3.2% 34.3% 5.4% 5.6% 1.0% 74.1% 2.4% 10.6% 7.9% 5.0% 0.5% Total 1.5% -1.3% 12.2% 3.8% -7.7% 5.1% 30.3% -14.1% 3.8% 8.2% 10.3% 6.1% Change From Prior Year - Quarter to Quarter Analysis 7.5% 3.7% 3.7% 15.3% NonMed_NonDrug 2.1% 7.5% 3.7% 3.7% 15.3% Med_NonDrug 0.16% 4.2% 6.8% 1.5% 1.5% Med_Drug 0.06% 4.2% 6.8% 1.5% 3.7% 1.5% Mod_Drug 20.7% 3.8% 23.0% 4.3% 4.3% 4.3% 4.3% 4.3% 6.8% 1.5%	-			Analysis									
NonMed_Drug 8.0% 11.5% 12.0% -1.1% 8.5% 5.7% 3.6% 10.6% 6.7% -0.4% 2.8% 2.0% Med_Drug 29.4% 3.2% 34.3% 5.4% 5.6% 1.0% 74.1% 2.4% 10.6% 7.9% 5.0% 0.5% Total 1.5% -1.3% 12.2% 3.8% -7.7% 5.1% 30.3% -14.1% 3.8% 8.2% 10.3% 6.1% Change From Prior Year - Quarter to Quarter Analysis 7.5% 5.1% 30.3% -14.1% 3.8% 8.2% 10.3% 6.1% Mod_NonDrug 2.1% 7.5% 3.7% 3.7% 7.2% NonMed_Drug -12.3% -16.0% -7.7% 5.3% 7.2% NonMed_Drug 0.6% 4.2% 6.8% 1.5% Med_Drug 20.7% 3.8% 23.0% 4.3% Total 4.0% 0.5% 5.3% 7.4% Change From Prior Year - Year to Year Analysis 5.2% 5.0	NonMed_NonDrug	2.8%	-3.6%	6.8%	23.1%	-14.4%	17.2%	3.9%	-6.7%	13.6%	5.5%	19.2%	21.8%
Med_Drug 29.4% 3.2% 34.3% 5.4% 5.6% 1.0% 74.1% 2.4% 10.6% 7.9% 5.0% 0.5% Total 1.5% -1.3% 12.2% 3.8% -7.7% 5.1% 30.3% -14.1% 3.8% 8.2% 10.3% 6.1% Change From Prior Year - Quarter to Quarter Analysis 7.5% 5.1% 30.3% -14.1% 3.8% 8.2% 10.3% 6.1% NonMed_NonDrug 2.1% 7.5% 3.7% 15.3% 6.1% Med_NonDrug -12.3% -16.0% -7.7% 7.2% NonMed_Drug 10.6% 4.2% 6.8% 1.5% Med_Drug 20.7% 3.8% 23.0% 4.3% Total 4.0% 0.5% 5.3% 8.1% Change From Prior Year - Year to Year Analysis 5.2% 5.0% 5.3% 7.4% Med_NonDrug 5.2% 5.0% 5.3% 7.4% 6.9% NonMed_NonDrug 5.2% 5.0% 5.5%			-10.0%								17.0%		
Total 1.5% -1.3% 12.2% 3.8% -7.7% 5.1% 30.3% -14.1% 3.8% 8.2% 10.3% 6.1% Change From Prior Year - Quarter to Quarter Analysis 7.7% 5.1% 30.3% -14.1% 3.8% 8.2% 10.3% 6.1% NonMed_NonDrug 2.1% 7.5% 3.7% 15.3% Med_NonDrug -12.3% -16.0% -7.7% 7.2% NonMed_Drug 10.6% 4.2% 6.8% 1.5% Med_Drug 20.7% 3.8% 23.0% 4.3% Total 4.0% 0.5% 5.3% 8.1% Change From Prior Year - Year to Year Analysis 7.4% 6.9% 7.4% NonMed_NonDrug 5.2% 5.0% 5.3% 7.4% Med_NonDrug 24.3% 14.3% -0.7% 6.9% NonMed_Drug 7.0% 7.3% 7.3% 5.5% Med_Drug 16.6% 15.1% 17.3% 12.2%	NonMed_Drug	8.0%		12.0%	-1.1%	8.5%	5.7%		10.6%	6.7%	-0.4%	2.8%	2.0%
Change From Prior Year - Quarter to Quarter Analysis 7.5% 3.7% 15.3% NonMed_NonDrug 2.1% 7.5% 3.7% 15.3% Med_NonDrug -12.3% -16.0% -7.7% 7.2% NonMed_Drug 10.6% 4.2% 6.8% 1.5% Med_Drug 20.7% 3.8% 23.0% 4.3% Total 4.0% 0.5% 5.3% 8.1% Change From Prior Year - Year to Year Analysis 7.4% 6.8% 7.4% Med_NonDrug 5.2% 5.0% 5.3% 7.4% Med_NonDrug 5.2% 5.0% 5.3% 5.5% Med_NonDrug 24.3% 14.3% -0.7% -6.9% NonMed_Drug 7.0% 7.3% 5.5% 5.5% Med_Drug 16.6% 15.1% 17.3% 12.2%	Med_Drug	<u>29.4%</u>	<u>3.2%</u>	<u>34.3%</u>	<u>5.4%</u>	<u>5.6%</u>	<u>1.0%</u>	<u>74.1%</u>	<u>2.4%</u>	<u>10.6%</u>	<u>7.9%</u>	<u>5.0%</u>	<u>0.5%</u>
NonMed_NonDrug 2.1% 7.5% 3.7% 15.3% Med_NonDrug -12.3% -16.0% -7.7% 7.2% NonMed_Drug 10.6% 4.2% 6.8% 1.5% Med_Drug 20.7% 3.8% 23.0% 4.3% Total 4.0% 0.5% 5.3% 8.1% Change From Prior Year - Year to Year Analysis 7.4% 8.1% NonMed_NonDrug 5.2% 5.0% 5.3% 7.4% Med_NonDrug 24.3% 14.3% -0.7% -6.9% NonMed_Drug 7.0% 7.3% 5.5% 5.5% Med_Drug 16.6% 15.1% 17.3% 12.2%						-7.7%	5.1%	30.3%	-14.1%	3.8%	8.2%	10.3%	6.1%
Med_NonDrug -12.3% -16.0% -7.7% 7.2% NonMed_Drug 10.6% 4.2% 6.8% 1.5% Med_Drug 20.7% 3.8% 23.0% 4.3% Total 4.0% 0.5% 5.3% 8.1% Change From Prior Year - Year to Year Analysis 7.4% 6.8% 7.4% NonMed_NonDrug 5.2% 5.0% 5.3% 7.4% Med_NonDrug 24.3% 14.3% -0.7% -6.9% NonMed_Drug 7.0% 7.3% 5.5% 5.5% Med_Drug 16.6% 15.1% 17.3% 12.2%	Change From Prior	Year - Quar	ter to Quart	er Analysis									
NonMed_Drug 10.6% 4.2% 6.8% 1.5% Med_Drug 20.7% 3.8% 23.0% 4.3% Total 4.0% 0.5% 5.3% 4.3% Change From Prior Year - Year to Year Analysis 7.4% 6.8% 1.5% NonMed_NonDrug 5.2% 5.0% 5.3% 7.4% Med_NonDrug 24.3% 14.3% -0.7% -6.9% NonMed_Drug 7.0% 7.3% 7.3% 5.5% Med_Drug 16.6% 15.1% 17.3% 12.2%	NonMed_NonDrug			2.1%			7.5%			3.7%			15.3%
Med_Drug 20.7% 3.8% 23.0% 4.3% Total 4.0% 0.5% 5.3% 8.1% Change From Prior Year - Year to Year Analysis 5.3% 7.4% NonMed_NonDrug 5.2% 5.0% 5.3% 7.4% Med_NonDrug 24.3% 14.3% -0.7% -6.9% NonMed_Drug 7.0% 7.3% 5.5% 5.5% Med_Drug 16.6% 15.1% 17.3% 12.2%	Med_NonDrug			-12.3%			-16.0%			-7.7%			7.2%
Total 4.0% 0.5% 5.3% 8.1% Change From Prior Year - Year to Year Analysis 5.0% 5.3% 7.4% NonMed_NonDrug 5.2% 5.0% 5.3% 7.4% Med_NonDrug 24.3% 14.3% -0.7% -6.9% NonMed_Drug 7.0% 7.3% 7.3% 5.5% Med_Drug 16.6% 15.1% 17.3% 12.2%	NonMed_Drug			10.6%			4.2%			6.8%			1.5%
Change From Prior Year - Year to Year Analysis NonMed_NonDrug 5.2% 5.0% 5.3% 7.4% Med_NonDrug 24.3% 14.3% -0.7% -6.9% NonMed_Drug 7.0% 7.3% 5.5% Med_Drug 16.6% 15.1% 17.3% 12.2%	Med_Drug			<u>20.7%</u>			<u>3.8%</u>			<u>23.0%</u>			<u>4.3%</u>
NonMed_NonDrug 5.2% 5.0% 5.3% 7.4% Med_NonDrug 24.3% 14.3% -0.7% -6.9% NonMed_Drug 7.0% 7.3% 7.3% 5.5% Med_Drug 16.6% 15.1% 17.3% 12.2%	Total			4.0%			0.5%			5.3%			8.1%
Med_NonDrug 24.3% 14.3% -0.7% -6.9% NonMed_Drug 7.0% 7.3% 5.5% Med_Drug 16.6% 15.1% 17.3% 12.2%	Change From Prior	Year - Year	to Year Ana	alysis									
Med_NonDrug 24.3% 14.3% -0.7% -6.9% NonMed_Drug 7.0% 7.3% 5.5% Med_Drug 16.6% 15.1% 17.3% 12.2%	NonMed_NonDrug			5.2%			5.0%			5.3%			7.4%
NonMed_Drug 7.0% 7.3% 7.3% 5.5% Med_Drug 16.6% 15.1% 17.3% 12.2%				24.3%			14.3%			-0.7%			-6.9%
Med_Drug 16.6% 15.1% 17.3% 12.2%				7.0%			7.3%			7.3%			5.5%
				16.6%			15.1%						
	- 0			13.1%			10.3%			7.2%			4.6%

Attachment - Trust Fund Historical Monthly Medical and Drug Trends FY 2015 to FY 2016

Med_NonDrug 2.226 2.545 NonMed_Drug 18,831 19,021 Med_Drug 2.319 2.651 Med_NonDrug \$223.62 \$257.26 Med_NonDrug 189.56 216.25 NonMed_Drug 229.61 211.93 Total \$737.29 \$788.89 Change From Prior Year - Month to Month Analysis NonMed_Drug NonMed_Drug -3.9% 17.6% Med_NonDrug -3.9% 17.6% Med_NonDrug -1.1% -11.5% Med_NonDrug -1.1% -0.5% Total 1.7% 3.8% Change From Prior Year - Quarter to Quarter Analysis NonMed_NonDrug NonMed_Drug -1.1% -0.5% Med_NonDrug -1.1% -0.5% Total 1.7% 3.8% Change From Prior Year - Quarter to Quarter Analysis NonMed_NonDrug NonMed_NonDrug -1.5% -0.5% Med_NonDrug NonMed_NonDrug NonMed_NonDrug NonMed_NonDrug NonMed_NonDrug NonMed_NonDrug NonMed_NonDrug NonMed_NonDrug				-			
Jul-15 Aug-15 NonMed_NonDrug 20,325 20,533 Wed_NonDrug 2,226 2,545 NonMed_Drug 18,831 19,021 Med_Drug 2,319 2,651 NonMed_NonDrug \$223.62 \$257.26 Med_NonDrug 18,956 216.25 NonMed_Drug 18,956 216.25 NonMed_Drug 229.61 211.93 Total \$737.29 \$788.89 Change From Prior Year - Month to Month Analysis NonMed_NonDrug NonMed_NonDrug -1.1% 13.8% NonMed_NonDrug -3.9% 17.6% Med_NonDrug -1.1% -11.5% Med_NonDrug -3.8% -11.5% Med_Drug 4.3% -9.5% Total 1.7% 3.8% Change From Prior Year - Quarter to Quarter Analysis NonMed_NonDrug Med_NonDrug NonMed_NonDrug NonMed_NonDrug Med_NonDrug NonMed_NonDrug NonMed_NonDrug Med_NonDrug Year Analysis				Fis	scal Year 2016		
NonMed_NonDrug 20,325 20,533 Med_NonDrug 2,226 2,545 NonMed_Drug 2,319 2,651 Med_NonDrug \$223,62 \$257.26 Med_NonDrug 189,56 216.25 NonMed_Drug 94.50 103.46 Med_NonDrug \$737.29 \$788.89 Change From Prior Year - Month to Month Analysis NonMed_NonDrug -3.9% NonMed_NonDrug -3.9% 17.6% Med_NonDrug -3.9% -11.5% Med_NonDrug -1.1% -11.5% Med_NonDrug -3.9% -17.6% Med_NonDrug -1.1% -11.5% Med_NonDrug -1.1% -11.5% Med_NonDrug -1.1% -11.5% Med_NonDrug -1.1% -11.5% Med_NonDrug NonMed_Drug -1.1% NonMed_NonDrug -1.1% -1.1% Med_NonDrug -1.1% -1.1% NonMed_NonDrug -1.1% -1.1% NonMed_NonDrug -1.1% -1.1% NonMed_NonDrug NonMed_NonDrug NonMed_NonDrug	Exposure						
Med_NonDrug 2.226 2,545 NonMed_Drug 18,831 19,021 Med_Drug 2,319 2,651 NonMed_NonDrug \$223.62 \$257.26 Med_NonDrug 189.56 216.25 NonMed_Drug 229.61 211.93 Total \$737.29 \$788.89 Change From Prior Year - Month to Month Analysis NonMed_Drug NonMed_Drug -3.9% 17.6% Med_NonDrug -3.9% 17.6% Med_NonDrug -1.1% -11.5% Med_NonDrug -1.1% -3.8% NonMed_NonDrug -1.1% -1.5% Med_NonDrug -1.1% -1.1% NonMed_NonDrug -1.1% -1.5% Med_NonDrug -1.2% -3.8% NonMed_NonDrug -1.1% -1.5% Med_NonDrug NonMed_NonDrug NonMed_NonDrug NonMed_NonDrug							
NonMed_Drug 18.831 19.021 Med_Drug 2.319 2.651 NonMed_Drug \$223.62 \$257.26 Med_NonDrug 189.56 216.25 NonMed_Drug 242.61 211.93 Total \$737.29 \$788.89 Change From Prior Year - Month to Month Analysis NonMed_Drug -3.9% NonMed_Drug -11.5% Med_Drug Med_Drug -11.5% Med_Drug Med_Drug -1.1% -11.5% Med_Drug -1.1% -1.6% Med_Drug -1.1% -1.6% Med_Drug -3.9% 17.6% Med_Drug -1.1% -1.6% Total 1.7% 3.8% Change From Prior Year - Quarter to Quarter Analysis NonMed_NonDrug NonMed_Drug NonPrug -4.3% Med_Drug -1.7% 3.8% Change From Prior Year - Year to Quarter Analysis NonMed_NonDrug Med_Drug -1.7% -5.% Med_Drug -1.7% -5.% Med_Drug -1.7% -5.% NonMed_	NonMed_NonDrug						
Med_Drug 2,319 2,651 Jul-15 Aug-15 NonMed_NonDrug \$\$223.62 \$\$257.26 Med_NonDrug 94.50 103.46 Med_Drug 29.61 211.93 Total \$737.29 \$788.09 Change From Prior Year - Month to Month Analysis NonMed_Drug -3.9% NonMed_NonDrug -3.9% 17.6% Med_NonDrug 7.1% 13.8% NonMed_Drug -1.1% -9.5% Total 1.7% 3.8% Change From Prior Year - Quarter to Quarter Analysis NonMed_NonDrug NonMed_Drug -1.1% -9.5% Total 1.7% 3.8% Change From Prior Year - Quarter to Quarter Analysis NonMed_NonDrug NonMed_NonDrug NonMed_NonDrug Med_Drug Variation Med_Drug Variation Year Analysis NonMed_NonDrug NonMed_NonDrug NonMed_NonDrug Med_NonDrug NonMed_NonDrug Med_NonDrug Variation NonMed_NonDrug Variation NonMed_NonDrug Variati	Med_NonDrug						
Jul-15 Aug-15 NonMed_NonDrug \$223.62 \$257.26 Med_NonDrug 189.56 216.25 NonMed_Drug 94.50 103.46 Med_Drug 92.9.61 211.93 Total \$737.29 \$788.89 Change From Prior Year - Month to Month Analysis NonMed_NonDrug -3.9% NonMed_NonDrug -3.9% 17.6% Med_NonDrug 7.1% 13.8% NonMed_Drug -1.5% -9.5% Med_Drug 4.3% -9.5% Total 1.7% 3.8% Change From Prior Year - Quarter to Quarter Analysis NonMed_NonDrug NonMed_NonDrug NonMed_NonDrug NonMed_NonDrug NonMed_NonDrug Vaar NonMed_NonDrug NonMed_NonDrug NonMed_NonDrug NonMed_NonDrug NonMed_NonDrug Vaar Analysis NonMed_NonDrug NonMed_NonDrug NonMed_NonDrug NonMed_NonDrug NonMed_NonDrug NonMed_NonDrug NonMed_NonDrug NonMed_Drug Vaar Analysis	NonMed_Drug						
NonMed_NonDrug \$223.62 \$257.26 Med_NonDrug 189.56 216.25 NonMed_Drug 94.50 103.46 Med_Drug 229.61 211.93 Total \$737.29 \$788.89 Change From Prior Year - Month to Month Analysis NonMed_NonDrug -3.9% NonMed_NonDrug -3.9% 17.6% Med_Drug -1.1% 13.8% NonMed_Drug -1.1% -11.5% Med_Drug -1.1% -3.8% Total 1.7% 3.8% NonMed_NonDrug -8.9% - Total 1.7% 3.8% Change From Prior Year - Quarter to Quarter Analysis NonMed_NonDrug NonMed_NonDrug -9.5% - NonMed_NonDrug -0.0000 - NonMed_NonDrug NonMed_NonDrug - NonMed_Drug - - Med_NonDrug - Year + Analysis NonMed_NonDrug - Year + Analysis NonMed_NonDrug - Year + Analysis<	Med_Drug	2,319	2,651				
Med_NonDrug 189.56 216.25 NonMed_Drug 94.50 103.46 Med_Drug 229.61 211.93 Total \$737.29 \$788.89 Change From Prior Year - Month to Month Analysis NonMed_NonDrug -3.9% NonMed_NonDrug -3.9% 17.6% Med_Drug -1.1% 13.8% NonMed_Drug -1.1% -11.5% Med_Drug -4.3% -9.5% Total 1.7% 3.8% Change From Prior Year - Quarter to Quarter Analysis NonMed_Drug NonMed_NonDrug -8.9% -9.5% Total 1.7% 3.8% Change From Prior Year - Quarter to Quarter Analysis NonMed_Drug NonMed_Drug -9.5% -9.5% Med_NonDrug -9.5% -9.5% NonMed_Norug -9.5% -9.5% NonMed_Norug -9.5% -9.5% Total 1.7% 3.8% Change From Prior Year - Year to Quarter Analysis -9.5% NonMed_NonDrug -9.5% -9.5% NonMed_NonDrug -9.5% -9.5% <th></th> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
NonMed_Drug 94.50 103.46 Med_Drug 229.61 211.93 Total \$737.29 \$788.89 Change From Prior Year - Month to Month Analysis NonMed_NonDrug -3.9% NonMed_NonDrug -3.9% 17.6% Med_Drug -1.1% -11.5% Med_Drug -1.1% -11.5% Med_Drug -3.8% -9.5% Total 1.7% 3.8% Change From Prior Year - Quarter to Quarter Analysis NonMed_NonDrug NonMed_NonDrug -9.5% -0.5% Total 1.7% 3.8% Change From Prior Year - Quarter to Quarter Analysis NonMed_NonDrug NonMed_Drug -9.5% -0.5% Med_Drug -0.5% -0.5% Med_Drug -0.5% -0.5% Med_NonDrug -9.5% -0.5% NonMed_Drug -0.5% -0.5% Med_Drug -0.5% -0.5% Med_NonDrug -0.5% -0.5% NonMed_Drug -0.5% -0.5% <th></th> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
Med_Drug 229.61 211.93 Total \$737.29 \$788.89 Change From Prior Year - Month to Month Analysis NonMed_NonDrug -3.9% 17.6% Med_NonDrug 7.1% 13.8% NonMed_Drug -1.1% -11.5% Med_Drug 4.3% -9.5% Total 1.7% 3.8% Change From Prior Year - Quarter to Quarter Analysis NonMed_NonDrug Med_NonDrug -9.5% -9.5% Change From Prior Year - Quarter to Quarter Analysis NonMed_NonDrug NonMed_NonDrug -8.8% -9.5% Change From Prior Year - Quarter to Quarter Analysis NonMed_Drug NonMed_Drug -9.5% -9.5% Total 1.7% 3.8% Change From Prior Year - Quarter to Quarter Analysis NonMed_Drug NonMed_Drug -9.5% -9.5% NonMed_NonDrug -9.5% -9.5% NonMed_NonDrug -9.5% -9.5% NonMed_NonDrug -9.5% -9.5% NonMed_Drug -9.5% -9.5% Med_NonDrug -9.5% -9.5%	Med_NonDrug						
Total \$737.29 \$788.89 Change From Prior Year - Month to Month Analysis NonMed_NonDrug -3.9% 17.6% Med_NonDrug 7.1% 13.8% NonMed_Drug -1.1% -11.5% Med_Drug -1.1% -9.5% Total 1.7% 3.8% Change From Prior Year - Quarter to Quarter Analysis NonMed_NonDrug Med_NonDrug NonMed_NonDrug Med_Drug Uarter Analysis NonMed_Drug Vear Analysis NonMed_NonDrug NonMed_NonDrug Med_NonDrug Vear Analysis NonMed_Drug Vear Analysis Non	NonMed_Drug						
Change From Prior Year - Month to Month Analysis NonMed_NonDrug -3.9% 17.6% Med_NonDrug 7.1% 13.8% NonMed_Drug -1.1% -11.5% Med_Drug <u>4.3%</u> -9.5% Total 1.7% 3.8% Change From Prior Year - Quarter to Quarter Analysis NonMed_NonDrug Med_NonDrug Med_Drug Total Change From Prior Year - Year to Year Analysis NonMed_NonDrug Med_NonDrug Med_NonDrug Med_NonDrug Med_NonDrug NonMed_Drug Med_Drug	Med_Drug	<u>229.61</u>	<u>211.93</u>				
NonMed_NonDrug -3.9% 17.6% Med_NonDrug 7.1% 13.8% NonMed_Drug -1.1% -11.5% Med_Drug <u>4.3%</u> -9.5% Total 1.7% 3.8% Change From Prior Year - Quarter to Quarter Analysis NonMed_NonDrug Med_NonDrug Med_Drug Med_Drug Total Change From Prior Year - Year to Year Analysis NonMed_NonDrug Med_NonDrug NonMed_Drug NonMed_Drug NonMed_Drug NonMed_Drug Med_Drug	Total	\$737.29	\$788.89				
Med_NonDrug 7.1% 13.8% NonMed_Drug -1.1% -11.5% Med_Drug <u>4.3%</u> <u>-9.5%</u> Total 1.7% 3.8% Change From Prior Year - Quarter to Quarter Analysis NonMed_NonDrug Med_NonDrug Med_NonDrug Med_Drug Vertice Med_Drug Vertice NonMed_Drug Vertice Med_Drug Vertice Med_Drug Vertice Med_NonDrug Vertice Med_NonDrug Vertice Med_Drug Vertice Med_NonDrug Vertice Med_NonDrug Vertice Med_NonDrug Vertice Med_NonDrug Vertice Med_Drug Vertice	-		-	6			
NonMed_Drug -1.1% -11.5% Med_Drug <u>4.3%</u> -9.5% Total 1.7% 3.8% Change From Prior Year - Quarter to Quarter Analysis NonMed_NonDrug Med_NonDrug Med_Drug Total Change From Prior Year - Year to Year Analysis NonMed_NonDrug Med_NonDrug Med_NonDrug Med_Drug Med_Drug Med_Drug	NonMed_NonDrug						
Med_Drug 4.3% -9.5% Total 1.7% 3.8% Change From Prior Year - Quarter to Quarter Analysis NonMed_NonDrug Med_NonDrug Med_Drug Med_Drug Total NonMed_Drug Med_Drug Med_Drug Med_NonDrug Med_Drug Med_NonDrug Med_NonDrug Med_NonDrug Med_NonDrug NonMed_NonDrug NonMed_NonDrug Med_NonDrug Med_NonDrug Med_Drug Med_Drug Med_Drug	Med_NonDrug		13.8%				
Total 1.7% 3.8% Change From Prior Year - Quarter to Quarter Analysis NonMed_NonDrug Med_NonDrug NonMed_Drug Total Change From Prior Year - Year to Year Analysis NonMed_NonDrug Med_NonDrug Med_Drug	NonMed_Drug						
Change From Prior Year - Quarter to Quarter Analysis NonMed_NonDrug Med_NonDrug NonMed_Drug Med_Drug Total Change From Prior Year - Year to Year Analysis NonMed_NonDrug Med_NonDrug Med_Drug Med_Drug	Med_Drug						
NonMed_NonDrug Med_NonDrug NonMed_Drug Med_Drug Total Change From Prior Year - Year to Year Analysis NonMed_NonDrug Med_NonDrug NonMed_Drug Med_Drug	Total	1.7%	3.8%				
Med_NonDrug NonMed_Drug Med_Drug Total Change From Prior Year - Year to Year Analysis NonMed_NonDrug Med_NonDrug NonMed_Drug Med_Drug	Change From Prior `	Year - Quart	ter to Quarter Anal	sis			
NonMed_Drug Med_Drug Total Change From Prior Year - Year to Year Analysis NonMed_NonDrug Med_NonDrug NonMed_Drug Med_Drug	NonMed_NonDrug						
Med_Drug Total Change From Prior Year - Year to Year Analysis NonMed_NonDrug Med_NonDrug NonMed_Drug Med_Drug	Med_NonDrug						
Total Change From Prior Year - Year to Year Analysis NonMed_NonDrug NonMed_Drug Med_Drug	NonMed_Drug						
Change From Prior Year - Year to Year Analysis NonMed_NonDrug Med_NonDrug NonMed_Drug Med_Drug	Med_Drug						
NonMed_NonDrug Med_NonDrug NonMed_Drug Med_Drug	Total						
Med_NonDrug NonMed_Drug Med_Drug	Change From Prior `	Year - Year	to Year Analysis				
NonMed_Drug Med_Drug	NonMed_NonDrug						
Med_Drug	Med_NonDrug						
Med_Drug	NonMed_Drug						
	Med_Drug						
	Total						